



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/62, 15/86, 15/12, 5/10, 1/21, 1/19, C07K 14/705, A61K 39/00, 31/713, G01N 33/50</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/15807</b>  <b>(43) International Publication Date:</b> 23 March 2000 (23.03.00)
<b>(21) International Application Number:</b> PCT/DK99/00481  <b>(22) International Filing Date:</b> 13 September 1999 (13.09.99)  <b>(30) Priority Data:</b> PA 1998 01164      15 September 1998 (15.09.98)      DK 60/102,896      2 October 1998 (02.10.98)      US  <b>(71) Applicant (for all designated States except US):</b> M & E BIOTECH A/S [DK/DK]; Kogle Allé 6, DK-2970 Hørsholm (DK).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HALKIER, Torben [DK/DK]; Hestkøbvej 11 E, DK-3460 Birkerød (DK). HAANING, Jesper [DK/DK]; Biskop Svanes Vej 2E, DK-3460 Birkerød (DK).  <b>(74) Agent:</b> KOEFOED, Peter; M & E Biotech A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).		<b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD FOR DOWN-REGULATING OSTEOPROTEGERIN LIGAND ACTIVITY  <b>(57) Abstract</b>  <p>The invention provides a novel method for down-regulating the biological activity of osteoprotegerin ligand (OPGL, TRANCE) thereby rendering possible the treatment/amelioration of diseases characterized by excessive loss of bone mass, e.g. osteoporosis. Down-regulation is effected by inducing an immune response against OPGL in an individual in need thereof. Immune responses can be raised by classical immunization with immunogenic variants of OPGL or by nucleic acid immunization where the nucleic acids encode the OPGL variant. The invention also pertains to compositions, polypeptides and nucleic acids useful in the invention, as well as to vectors and transformed host cells useful in the preparation thereof.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## METHOD FOR DOWN-REGULATING OSTEOPROTEGERIN LIGAND ACTIVITY

## FIELD OF THE INVENTION

The present invention relates to improvements in therapy and prevention of osteoporosis and other diseases characterized by continued loss of bone tissue. More specifically, the present invention provides a method for down-regulating osteoprotegerin ligand (OPGL) by enabling the production of antibodies against OPGL in subjects suffering from or in danger of suffering from osteoporosis. The invention also provides for methods of producing modified OPGL useful in this method as well as for the modified OPGL as such. Also encompassed by the present invention are nucleic acid fragments encoding modified OPGL as well as vectors incorporating these nucleic acid fragments and host cells and cell lines transformed therewith. The invention also provides for a method for the identification of OPGL analogues which are useful in the method of the invention as well as for compositions comprising modified OPGL or comprising nucleic acids encoding the OPGL analogues.

## FIELD OF THE INVENTION

Osteoporosis is a major and growing health problem worldwide. It affects an estimated 75 million people in the United States of America, Europe and Japan combined. Thus, it is the most common systemic bone disorder in the industrialised part of the world.

Osteoporosis affects one in four postmenopausal women and a majority of the elderly, including a substantial number of men. The cost of osteoporosis in the United States of America with 15 million affected people was estimated to be 3.8 billion USD annually in 1984. This translates by extrapolation to a worldwide cost of something in the order of at least 20 billion USD.

Osteoporosis is a systemic skeletal disease characterised by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fractures. Although all bones are affected, 5 fractures of the spine, wrist and hip are typical and the most common. The risk of developing osteoporosis increases with age and is higher in women than in men. Its etiology appears to reside in the mechanisms underlying an accentuation of the normal loss of bone mass, which follows the menopause in women 10 and occurs in all individuals with advancing age.

Peak bone mass is achieved at about 35 years of age. After reaching its peak, bone mass declines throughout life due to an imbalance in remodelling. Bones lose both mineral and organic matrix but retain their basic organisation.

15 Bone consists of a mineralised extracellular matrix composed of a variety of proteins and proteoglycans; the principal component being type I collagen. The mineral encrusting the extracellular matrix is hydroxyapatite  $(\text{Ca}_3(\text{PO}_4)_2 \cdot \text{Ca}(\text{OH})_2)$ . Bone is continuously modelled during growth and development and 20 remodelled throughout life in response to physical and chemical signals.

The growth, development and maintenance of bone are highly regulated processes, which at the cellular level involves the co-ordinate regulation of bone-forming cells (osteoblasts) and 25 bone-resorbing cells (osteoclasts). The level of bone mass reflects the balance of bone formation and resorption.

Osteoblasts arise from mesenchymal stem cells and produce bone matrix during development, after bone injury, and during the normal bone remodelling that occurs throughout life. Osteo- 30 clasts differentiate from hematopoietic precursors of the monocyte-macrophage lineage and resorb bone matrix.



An imbalance of osteoblast and osteoclast functions can result in the skeletal abnormalities characterised by increased bone mass (osteopetrosis) or by decreased bone mass (osteoporosis).

Studies of osteopetrosis in mutant mice have shown that genetic defects in osteoclast development, maturation, and/or activation lead to decreased bone resorption and uniformly result in severe osteopetrosis (Marks, 1989). Nevertheless, relatively little has so far been known about the soluble factors that act physiologically to regulate osteoclast development.

Recently, however, two proteins that take part in this regulation have been described and characterized (Simonet et al., 1997; Lacey et al., 1998). These two proteins are *osteoprotegerin* and *osteoprotegerin ligand*.

Osteoprotegerin is a novel secreted member of the tumour necrosis factor receptor family. *In vitro*, osteoprotegerin blocks osteoclastogenesis in a dose dependent manner. Transgenic mice expressing osteoprotegerin exhibit a generalized increase in bone density (osteopetrosis) associated with a decrease in osteoclasts. Administration of recombinant osteoprotegerin produces similar effects in normal mice and protects against ovariectomy-associated bone loss in rats (Simonet et al., 1997). In addition, osteoprotegerin-deficient mice (knock out mice) while normal at birth develop early onset osteoporosis and arterial calcification (Bucay et al., 1998). These observations strongly point to the possibility that osteoprotegerin blocks the differentiation of osteoclasts, the principal if not sole bone-resorbing cell type, suggesting that it can act as a humoral regulator of bone resorption. Osteoprotegerin is the subject matter of WO 97/23614.

It was hypothesized that osteoprotegerin may exert its effect by binding to and neutralising a factor that stimulates osteoclast development, thus inhibiting osteoclast maturation (Simonet et al., 1997).

5 Osteoprotegerin ligand (OPGL) is a novel member of the tumour  
necrosis factor family of cytokines that exists in both a  
membrane-bound and a soluble form. OPGL binds to osteoprote-  
gerin with a binding affinity of 4 nM. *In vitro*, OPGL acti-  
vates mature osteoclasts and modulates osteoclast formation  
10 from bone marrow precursors in the presence of CSF-1. It has  
also been demonstrated that OPGL binds to the surface of  
osteoclast progenitors in CSF-1-treated bone marrow. The  
receptor for OPGL on these hematopoietic progenitor cells is,  
however, unknown. Recombinant soluble OPGL is a potent inducer  
15 of bone resorption *in vivo* (Lacey et al., 1998).

#### Description of OPGL

OPGL is synthesised as a type II transmembrane protein consis-  
ting of 317 amino acid residues (human, cf. SEQ ID NO: 2) or  
316 amino acid residues (murine, cf. SEQ ID NOs: 4 and 6).  
20 Alignment of the two amino acid sequences show that identical  
amino acid residues are found at 87% of the homologous posi-  
tions.

The OPGL amino acid sequence contains a short cytoplasmic  
domain in the N-terminus followed by the putative transmem-  
25 brane region between amino acid residues 49 and 69. Based on  
its homology to tumour necrosis factor alpha, the extracellu-  
lar part of OPGL has been suggested to be comprised by two  
domains: a stalk region extending from amino acid residue 70  
to 157, and the active ligand moiety extending from amino acid  
30 residue 158 to the C-terminus.

The most closely related protein to OPGL appears to be the apoptosis inducing cytokine TRAIL with less than 25% identical amino acid residues. OPGL has also very recently been cloned in other contexts and was called TRANCE (Wong et al., 1997, J. Biol. Chem. **272**: 25190-25194) and RANKL, respectively (Anderson et al., 1997, Nature **390**: 175-179. The protein is also known as osteoclast differentiation factor (ODF).

Several N-terminal deletion variants of murine OPGL have been expressed in *E. coli* and purified. These variants consisted of amino acid residues 75-316, 128-316, 137-316, and 158-316, respectively. The three shortest variants had similar  $\beta$ -sheet structure based on circular dichroism studies, and all were able to bind to osteoprotegerin. More important, though, is that the three variants were active in *in vitro* assays (Lacey et al., 1998).

The shortest variant was studied further. Like tumour necrosis factor alpha, this variant OPGL exists as a trimer in solution and forms 3:3 complexes when incubated with osteoprotegerin. The binding affinity was found to be 4 nM. This variant induces significant increases in blood ionized calcium (hypercalcemia) in mice *in vivo*. Co-administration of osteoprotegerin significantly reduced this hypercalcemic effect of OPGL.

The longest variant (amino acid residues 75-316) of OPGL did not bind to osteoprotegerin and it did not have any biological activity.

At the time of construction of the N-terminal deletion variants the natural cleavage site in OPGL was not known. Expression of full-length OPGL in human 293 fibroblasts resulted in soluble OPGL beginning at amino residue 139 in the murine protein or at the homologous amino acid residue 140 in the

human protein. These expression studies also showed that soluble OPGL resulting from expression in human cells is glycosylated. This is not surprising as both murine and human OPGL contain three potential N-glycosylation sites in the C-terminal ligand domain.

The concentrations of osteoprotegerin in blood and tissues are not known but the protein has significant biological activity at a concentration of 1 ng/ml.

#### Biological activity of OPGL

10 OPGL is a potent osteoclast differentiation factor when combined with CSF-1. Neither of these components alone are capable of inducing osteoclast differentiation from progenitor cells.

OPGL is a potent activator of mature osteoclast. On its own,  
15 OPGL activates mature osteoclasts to resorb bone. OPGL has not been observed to act as an osteoclast growth factor or osteoclast survival factor in these experiments.

The action of OPGL does not seem to be species restricted as murine OPGL also induced osteoclast formation in cultures of  
20 human peripheral blood mononuclear cells.

#### OBJECT OF THE INVENTION

The object of the present invention is to provide novel therapies against conditions characterized by excess bone resorption, such as osteoporosis. A further object is to develop an  
25 autovaccine against OPGL, in order to obtain a novel treatment for osteoporosis and for other pathological disorders involving excess bone resorption.

## SUMMARY OF THE INVENTION

We find that the above-referenced data suggests a pathophysiological role of OPGL. The *in vivo* evidence is partially circumstantial or indirect but is in our opinion  
5 convincing especially in combination with the direct evidence.

Observing that injection into mice of the recombinant C-terminal domain of OPGL results in severe hypercalcemia in our opinion points directly to a pathophysiological role.

Indirect evidence comes from the osteoprotegerin-deficient  
10 mice (knock out mice) that even though normal at birth develop early onset osteoporosis. This shows that removing a protein that binds OPGL and neutralises its effects leads to osteoporosis. We conclude that the most likely reason for this is an increased osteoclast maturation and activation caused by OPGL.

15 Two other pieces of indirect evidence are that both mice transgenic for osteoprotegerin and mice injected with recombinant osteoprotegerin develop osteopetrosis. This shows that unnatural high levels of a protein that binds OPGL and neutralises its effects leads to osteopetrosis. Here, we conclude  
20 that this has its reasons in a decreased osteoclast maturation and activation caused by neutralisation of OPGL.

We therefore suggest a model in which OPGL and osteoprotegerin act as positive and negative regulators of osteoclast development, respectively. In other words OPGL promotes bone resorption while osteoprotegerin inhibits bone resorption.  
25

Thus, in relation to osteoporosis OPGL could be thought of as a "pathogenic agent" which promotes the bone resorption that in the end leads to osteoporosis. Likewise osteoprotegerin can

be visualised as a "therapeutic agent" which counteracts the "pathogenic agent" through neutralisation of its effects.

We hence propose to down-regulate osteoclast differentiation/maturation/formation and osteoclast activation through *in vivo* production of antibodies capable of neutralizing OPGL, thereby providing a safe and efficient means for treating/ameliorating and/or preventing osteoporosis and other diseases characterized by an excess rate of bone resorption compared to the rate of bone formation.

Thus, in its broadest and most general scope, the present invention relates to a method for *in vivo* down-regulation of osteoprotegerin ligand (OPGL) activity in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunologically effective amount of

- at least one OPGL polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the OPGL polypeptide or subsequence thereof induces production of antibodies against the OPGL polypeptide, and/or
- at least one OPGL analogue wherein is introduced a modification in the OPGL polypeptide which has as a result that immunization of the animal with the analogue induces production of antibodies against the OPGL polypeptide.

The most attractive aspect of this approach is that e.g. osteoporosis can be controlled by periodic but not very frequent immunizations, in contrast to a therapeutic approach which involves frequent (e.g. daily) administration of osteoprotegerin or molecules having a binding affinity to OPGL analogous therewith. It is expected that 1-4 annual injections with an immunogenic composition will be sufficient to obtain

the desired effect, whereas administration of osteoprotegerin or other inhibitors of OPGL activity would require daily administrations.

The invention also relates to OPGL analogues as well as to  
5 nucleic acid fragments encoding a subset of these. Also  
immunogenic compositions comprising the analogues or the  
nucleic acid fragments are part of the invention.

The invention also relates to a method of identifying analogues of OPGL as well as a method for preparing composition  
10 comprising the OPGL analogues.

Finally, the invention relates to a method treating osteoporosis and other diseases characterized in excess bone resorption, wherein is administered a non-OPGL molecule (typically an antibody) which blocks the interaction between OPGL and its  
15 receptor on osteoclast cells.

## DETAILED DISCLOSURE OF THE INVENTION

### Definitions

In the following a number of terms used in the present specification and claims will be defined and explained in  
20 detail in order to clarify the metes and bounds of the invention.

The terms "T-lymphocyte" and "T-cell" will be used interchangeably for lymphocytes of thymic origin which are responsible for various cell mediated immune responses as well  
25 as for helper activity in the humoral immune response. Likewise, the terms "B-lymphocyte" and "B-cell" will be used interchangeably for antibody-producing lymphocytes.

An "OPGL polypeptide" is herein intended to denote polypeptides having the amino acid sequence of the above-discussed OPGL proteins derived from humans and mice (or truncates thereof sharing a substantial amount of B-cell epitopes with  
5 intact OPGL), but also polypeptides having the amino acid sequence identical to analogues of these two proteins isolated from other species are embraced by the term. Also unglycosylated forms of OPGL which are prepared in prokaryotic system are included within the boundaries of the term as are forms having  
10 varying glycosylation patterns due to the use of e.g. yeasts or other non-mammalian eukaryotic expression systems. It should, however, be noted that when using the term "an OPGL polypeptide" it is intended that the polypeptide in question is normally non-immunogenic when presented to the animal to be  
15 treated. In other words, the OPGL polypeptide is a self-protein or is an analogue of such a self-protein which will not normally give rise to an immune response against OPGL of the animal in question.

An "OPGL analogue" is an OPGL polypeptide which has been  
20 subjected to changes in its primary structure. Such a change can e.g. be in the form of fusion of an OPGL polypeptide to a suitable fusion partner (i.e. a change in primary structure exclusively involving C- and/or N-terminal additions of amino acid residues) and/or it can be in the form of insertions  
25 and/or deletions and/or substitutions in the OPGL polypeptide's amino acid sequence. Also encompassed by the term are derivatized OPGL molecules, cf. the discussion below of modifications of OPGL.

It should be noted that the use as a vaccine in a human of a  
30 xeno-analogue (e.g. a canine or porcine analogue) of human OPGL can be imagined to produce the desired immunity against OPGL. Such use of an xeno-analogue for immunization is also considered part of the invention.



The term "polypeptide" is in the present context intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 100 amino acid residues, and polypeptides of more than 100 amino acid residues. Furthermore, the term is also intended to include proteins, i.e. functional biomolecules comprising at least one polypeptide; when comprising at least two polypeptides, these may form complexes, be covalently linked, or may be non-covalently linked. The polypeptide(s) in a protein can be glycosylated and/or lipidated and/or comprise prosthetic groups.

The term "subsequence" means any consecutive stretch of at least 3 amino acids or, when relevant, of at least 3 nucleotides, derived directly from a naturally occurring OPGL amino acid sequence or nucleic acid sequence, respectively.

15 The term "animal" is in the present context in general intended to denote an animal species (preferably mammalian), such as *Homo sapiens*, *Canis domesticus*, etc. and not just one single animal. However, the term also denotes a population of such an animal species, since it is important that the individuals immunized according to the method of the invention all harbour substantially the same OPGL allowing for immunization of the animals with the same immunogen(s). If, for instance, genetic variants of OPGL exists in different human population it may be necessary to use different immunogens in these different populations in order to be able to break the autotolerance towards OPGL in each population. It will be clear to the skilled person that an animal in the present context is a living being which has an immune system. It is preferred that the animal is a vertebrate, such as a mammal.

30 By the term "in vivo down-regulation of OPGL activity" is herein meant reduction in the living organism of the number of interactions between OPGL and its (unknown) receptor (or

between OPGL and other possible biologically important binding partners for this molecule). The down-regulation can be obtained by means of several mechanisms: Of these, simple interference with the active site in OPGL by antibody binding is the most simple. However, it is also within the scope of the present invention that the antibody binding results in removal of OPGL by scavenger cells (such as macrophages and other phagocytic cells).

The expression "effecting presentation ... to the immune system" is intended to denote that the animal's immune system is subjected to an immunogenic challenge in a controlled manner. As will appear from the disclosure below, such challenge of the immune system can be effected in a number of ways of which the most important are vaccination with polypeptide containing "pharmaccines" (i.e. a vaccine which is administered to treat or ameliorate ongoing disease) or nucleic acid "pharmaccine" vaccination. The important result to achieve is that immune competent cells in the animal are confronted with the antigen in an immunologically effective manner, whereas the precise mode of achieving this result is of less importance to the inventive idea underlying the present invention.

The term "immunogenically effective amount" has its usual meaning in the art, i.e. an amount of an immunogen which is capable of inducing an immune response which significantly engages pathogenic agents which share immunological features with the immunogen.

When using the expression that the OPGL has been "modified" is herein meant a chemical modification of the polypeptide which constitutes the backbone of OPGL. Such a modification can e.g. be derivatization (e.g. alkylation) of certain amino acid residues in the OPGL sequence, but as will be appreciated from the disclosure below, the preferred modifications comprise

changes of the primary structure of the OPGL amino acid sequence.

When discussing "autotolerance towards OPGL" it is understood that since OPGL is a self-protein in the population to be vaccinated, normal individuals in the population do not mount an immune response against OPGL; it cannot be excluded, though, that occasional individuals in an animal population might be able to produce antibodies against native OPGL, e.g. as part of a autoimmune disorder. At any rate, an animal will normally only be autotolerant towards its own OPGL, but it cannot be excluded that OPGL analogues derived from other animal species or from a population having a different OPGL phenotype would also be tolerated by said animal.

A "foreign T-cell epitope" (or: "foreign T-lymphocyte epitope") is a peptide which is able to bind to an MHC molecule and which stimulates T-cells in an animal species. Preferred foreign T-cell epitopes in the invention are "promiscuous" epitopes, i.e. epitopes which bind to a substantial fraction of a particular class of MHC molecules in an animal species or population. Only a very limited number of such promiscuous T-cell epitopes are known, and they will be discussed in detail below. It should be noted that in order for the immunogens which are used according to the present invention to be effective in as large a fraction of an animal population as possible, it may be necessary to 1) insert several foreign T-cell epitopes in the same OPGL analogue or 2) prepare several OPGL analogues wherein each analogue has a different promiscuous epitope inserted. It should be noted also that the concept of foreign T-cell epitopes also encompasses use of cryptic T-cell epitopes, i.e. epitopes which are derived from a self-protein and which only exerts immunogenic behaviour when existing in isolated form without being part of the self-protein in question.

A "foreign T helper lymphocyte epitope" (a foreign T<sub>H</sub> epitope) is a foreign T cell epitope which binds an MHC Class II molecule and can be presented on the surface of an antigen presenting cell (APC) bound to the MHC Class II molecule.

5 A "functional part" of a (bio)molecule is in the present context intended to mean the part of the molecule which is responsible for at least one of the biochemical or physiological effects exerted by the molecule. It is well-known in the art that many enzymes and other effector molecules have an  
10 active site which is responsible for the effects exerted by the molecule in question. Other parts of the molecule may serve a stabilizing or solubility enhancing purpose and can therefore be left out if these purposes are not of relevance in the context of a certain embodiment of the present inven-  
15 tion. For instance it is possible to use certain cytokines as a modifying moiety in OPGL (cf. the detailed discussion below), and in such a case, the issue of stability may be irrelevant since the coupling to OPGL provides the stability necessary.

20 The term "adjuvant" has its usual meaning in the art of vaccine technology, i.e. a substance or a composition of matter which is 1) not in itself capable of mounting a specific immune response against the immunogen of the vaccine, but which is 2) nevertheless capable of enhancing the immune  
25 response against the immunogen. Or, in other words, vaccination with the adjuvant alone does not provide an immune response against the immunogen, vaccination with the immunogen may or may not give rise to an immune response against the immunogen, but the combined vaccination with immunogen and  
30 adjuvant induces an immune response against the immunogen which is stronger than that induced by the immunogen alone.

"Targeting" of a molecule is in the present context intended to denote the situation where a molecule upon introduction in the animal will appear preferentially in certain tissue(s) or will be preferentially associated with certain cells or cell types. The effect can be accomplished in a number of ways including formulation of the molecule in composition facilitating targeting or by introduction in the molecule of groups which facilitates targeting. These issues will be discussed in detail below.

10 "Stimulation of the immune system" means that a substance or composition of matter exhibits a general, non-specific immunostimulatory effect. A number of adjuvants and putative adjuvants (such as certain cytokines) share the ability to stimulate the immune system. The result of using an immunostimulating agent is an increased "alertness" of the immune system meaning that simultaneous or subsequent immunization with an immunogen induces a significantly more effective immune response compared to isolated use of the immunogen

#### Preferred embodiments of OPGL activity down-regulation

20 It is preferred that the OPGL polypeptide used as an immunogen in the method of the invention is a modified molecule wherein at least one change is present in the OPGL amino acid sequence, since the chances of obtaining the all-important breaking of autotolerance towards OPGL is greatly facilitated that way. It should be noted that this does not exclude the possibility of using such a modified OPGL in formulations which further facilitate the breaking of autotolerance against OPGL, e.g. formulations containing adjuvants.

It has been shown (in Dalum I et al., 1996, J. Immunol. 157: 4796-4804) that potentially self-reactive B-lymphocytes recognizing self-proteins are physiologically present in normal

individuals. However, in order for these B-lymphocytes to be induced to actually produce antibodies reactive with the relevant self-proteins, assistance is needed from cytokine producing T-helper lymphocytes ( $T_H$ -cells or  $T_H$ -lymphocytes). Normally this help is not provided because T-lymphocytes in general do not recognize T-cell epitopes derived from self-proteins when presented by antigen presenting cells (APCs). However, by providing an element of "foreignness" in a self-protein (*i.e.* by introducing an immunologically significant modification), T-cells recognizing the foreign element are activated upon recognizing the foreign epitope on an APC (such as, initially, a mononuclear cell). Polyclonal B-lymphocytes (which are also APCs) capable of recognising self-epitopes on the modified self-protein also internalise the antigen and subsequently presents the foreign T-cell epitope(s) thereof, and the activated T-lymphocytes subsequently provide cytokine help to these self-reactive polyclonal B-lymphocytes. Since the antibodies produced by these polyclonal B-lymphocytes are reactive with different epitopes on the modified polypeptide, including those which are also present in the native polypeptide, an antibody cross-reactive with the non-modified self-protein is induced. In conclusion, the T-lymphocytes can be led to act as if the population of polyclonal B-lymphocytes have recognised an entirely foreign antigen, whereas in fact only the inserted epitope(s) is/are foreign to the host. In this way, antibodies capable of *cross-reacting* with non-modified self-antigens are induced.

Several ways of modifying a peptide self-antigen in order to obtain breaking of autotolerance are known in the art. Hence, according to the invention, the modification can include that

- at least one foreign T-cell epitope is introduced, and/or

- at least one first moiety is introduced which effects targeting of the modified molecule to an antigen presenting cell (APC), and/or
- at least one second moiety is introduced which stimulates  
5 the immune system, and/or
- at least one third moiety is introduced which optimizes presentation of the modified OPGL polypeptide to the immune system.

However, all these modifications should be carried out while  
10 maintaining a substantial fraction of the original B-lymphocyte epitopes in OPGL, since the B-lymphocyte recognition of the native molecule is thereby enhanced.

In one preferred embodiment, side groups (in the form of foreign T-cell epitopes or the above-mentioned first, second  
15 and third moieties) are covalently or non-covalently introduced. This is to mean that stretches of amino acid residues derived from OPGL are derivatized without altering the primary amino acid sequence, or at least without introducing changes in the peptide bonds between the individual amino acids in the  
20 chain.

An alternative, and preferred, embodiment utilises amino acid substitution and/or deletion and/or insertion and/or addition (which may be effected by recombinant means or by means of peptide synthesis; modifications which involves longer  
25 stretches of amino acids can give rise to fusion polypeptides). One especially preferred version of this embodiment is the technique described in WO 95/05849, which discloses a method for down-regulating self-proteins by immunising with analogues of the self-proteins wherein a number of amino acid  
30 sequence(s) has been substituted with a corresponding number of amino acid sequence(s) which each comprise a foreign immunodominant T-cell epitope, while at the same time maintaining the overall tertiary structure of the self-protein in

the analogue. For the purposes of the present invention, it is however sufficient if the modification (be it an insertion, addition, deletion or substitution) gives rise to a foreign T-cell epitope and at the same time preserves a substantial  
 5 number of the B-cell epitopes in OPGL. However, in order to obtain maximum efficacy of the immune response induced, it is preferred that the overall tertiary structure of OPGL is maintained in the modified molecule.

The following formula describes the OPGL constructs generally  
 10 covered by the invention:

$$(\text{MOD}_1)_{s_1} (\text{OPGL}_{e_1})_{n_1} (\text{MOD}_2)_{s_2} (\text{OPGL}_{e_2})_{n_2} \dots (\text{MOD}_x)_{s_x} (\text{OPGL}_{e_x})_{n_x} \quad (\text{I})$$

-where  $\text{OPGL}_{e_1}$ - $\text{OPGL}_{e_x}$  are  $x$  B-cell epitope containing subsequences of OPGL which independently are identical or non-identical and which may contain or not contain foreign side groups,  $x$  is  
 15 an integer  $\geq 3$ ,  $n_1$ - $n_x$  are  $x$  integers  $\geq 0$  (at least one is  $\geq 1$ ),  $\text{MOD}_1$ - $\text{MOD}_x$  are  $x$  modifications introduced between the preserved B-cell epitopes, and  $s_1$ - $s_x$  are  $x$  integers  $\geq 0$  (at least one is  $\geq 1$  if no side groups are introduced in the  $\text{OPGL}_e$  sequences). Thus, given the general functional restraints on the  
 20 immunogenicity of the constructs, the invention allows for all kinds of permutations of the original OPGL sequence, and all kinds of modifications therein. Thus, included in the invention are modified OPGL obtained by omission of parts of the OPGL sequence which e.g. exhibit adverse effects *in vivo* or  
 25 omission of parts which are normally intracellular and thus could give rise to undesired immunological reactions.

Maintenance of a substantial fraction of B-cell epitopes or even the overall tertiary structure of a protein which is  
 30 subjected to modification as described herein can be achieved in several ways. One is simply to prepare a polyclonal antiserum directed against OPGL (e.g. an antiserum prepared in a



- rabbit) and thereafter use this antiserum as a test reagent (e.g. in a competitive ELISA) against the modified proteins which are produced. Modified versions (analogues) which react to the same extent with the antiserum as does OPGL must be  
5 regarded as having the same overall tertiary structure as OPGL whereas analogues exhibiting a limited (but still significant and specific) reactivity with such an antiserum are regarded as having maintained a substantial fraction of the original B-cell epitopes.
- 10 Alternatively, a selection of monoclonal antibodies reactive with distinct epitopes on OPGL can be prepared and used as a test panel. This approach has the advantage of allowing 1) an epitope mapping of OPGL and 2) a mapping of the epitopes which are maintained in the analogues prepared.
- 15 Of course, a third approach would be to resolve the 3-dimensional structure of OPGL or of a biologically active truncate thereof (cf. above) and compare this to the resolved three-dimensional structure of the analogues prepared. Three-dimensional structure can be resolved by the aid of X-ray diffrac-  
20 tion studies and NMR-spectroscopy. Further information relating to the tertiary structure can to some extent be obtained from circular dichroism studies which have the advantage of merely requiring the polypeptide in pure form (whereas X-ray diffraction requires the provision of crystallized polypeptide  
25 and NMR requires the provision of isotopic variants of the polypeptide) in order to provide useful information about the tertiary structure of a given molecule. However, ultimately X-ray diffraction and/or NMR are necessary to obtain conclusive data since circular dichroism can only provide indirect evi-  
30 dence of correct 3-dimensional structure via information of secondary structure elements.

One preferred embodiment of the invention utilises multiple presentations of B-lymphocyte epitopes of OPGL (i.e. formula I wherein at least one B-cell epitope is present in two positions). This effect can be achieved in various ways, e.g. by simply preparing fusion polypeptides comprising the structure (OPGL)<sub>m</sub>, where m is an integer  $\geq 2$  and then introduce the modifications discussed herein in at least one of the OPGL sequences. It is preferred that the modifications introduced includes at least one duplication of a B-lymphocyte epitope and/or the introduction of a hapten.

As mentioned above, the introduction of a foreign T-cell epitope can be accomplished by introduction of at least one amino acid insertion, addition, deletion, or substitution. Of course, the normal situation will be the introduction of more than one change in the amino acid sequence (e.g. insertion of or substitution by a complete T-cell epitope) but the important goal to reach is that the OPGL analogue, when processed by an antigen presenting cell (APC), will give rise to such a foreign immunodominant T-cell epitope being presented in context of an MCH Class II molecule on the surface of the APC. Thus, if the OPGL amino acid sequence in appropriate positions comprises a number of amino acid residues which can also be found in a foreign T<sub>H</sub> epitope then the introduction of a foreign T<sub>H</sub> epitope can be accomplished by providing the remaining amino acids of the foreign epitope by means of amino acid insertion, addition, deletion and substitution. In other words, it is not necessary to introduce a complete T<sub>H</sub> epitope by insertion or substitution in order to fulfill the purpose of the present invention.

It is preferred that the number of amino acid insertions, deletions, substitutions or additions is at least 2, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,

20, and 25 insertions, substitutions, additions or deletions. It is furthermore preferred that the number of amino acid insertions, substitutions, additions or deletions is not in excess of 150, such as at most 100, at most 90, at most 80, 5 and at most 70. It is especially preferred that the number of substitutions, insertions, deletions, or additions does not exceed 60, and in particular the number should not exceed 50 or even 40. Most preferred is a number of not more than 30. With respect to amino acid additions, it should be noted that 10 these, when the resulting construct is in the form of a fusion polypeptide, is often considerably higher than 150.

Preferred embodiments of the invention includes modification by introducing at least one foreign immunodominant T-cell epitope. It will be understood that the question of immune 15 dominance of a T-cell epitope depends on the animal species in question. As used herein, the term "immunodominance" simply refers to epitopes which in the vaccinated individual/population gives rise to a significant immune response, but it is a well-known fact that a T-cell epitope which is 20 immunodominant in one individual/population is not necessarily immunodominant in another individual of the same species, even though it may be capable of binding MHC-II molecules in the latter individual. Hence, for the purposes of the present invention, an immune dominant T-cell epitope is a T-cell 25 epitope which will be effective in providing T-cell help when present in an antigen. Typically, immune dominant T-cell epitopes has as an inherent feature that they will substantially always be presented bound to an MHC Class II molecule, irrespective of the polypeptide wherein they appear.

30 Another important point is the issue of MHC restriction of T-cell epitopes. In general, naturally occurring T-cell epitopes are MHC restricted, *i.e.* a certain peptides constituting a T-cell epitope will only bind effectively to a subset of MHC

Class II molecules. This in turn has the effect that in most cases the use of one specific T-cell epitope will result in a vaccine component which is only effective in a fraction of the population, and depending on the size of that fraction, it can  
5 be necessary to include more T-cell epitopes in the same molecule, or alternatively prepare a multi-component vaccine wherein the components are OPGL variants which are distinguished from each other by the nature of the T-cell epitope introduced.

10 If the MHC restriction of the T-cells used is completely unknown (for instance in a situation where the vaccinated animal has a poorly defined MHC composition), the fraction of the population covered by a specific vaccine composition can be determined by means of the following formula

15

$$f_{\text{population}} = 1 - \prod_{i=1}^n (1 - p_i) \quad (\text{II})$$

-where  $p_i$  is the frequency in the population of responders to the  $i^{\text{th}}$  foreign T-cell epitope present in the vaccine composition, and  $n$  is the total number of foreign T-cell epitopes in  
20 the vaccine composition. Thus, a vaccine composition containing 3 foreign T-cell epitopes having response frequencies in the population of 0.8, 0.7, and 0.6, respectively, would give

$$1 - 0.2 \times 0.3 \times 0.4 = 0.976$$

-i.e. 97.6 percent of the population will statistically mount  
25 an MHC-II mediated response to the vaccine.

The above formula does not apply in situations where a more or less precise MHC restriction pattern of the peptides used is known. If, for instance a certain peptide only binds the human MHC-II molecules encoded by HLA-DR alleles DR1, DR3, DR5, and

DR7, then the use of this peptide together with another peptide which binds the remaining MHC-II molecules encoded by HLA-DR alleles will accomplish 100% coverage in the population in question. Likewise, if the second peptide only binds DR3 and DR5, the addition of this peptide will not increase the coverage at all. If one bases the calculation of population response purely on MHC restriction of T-cell epitopes in the vaccine, the fraction of the population covered by a specific vaccine composition can be determined by means of the following formula:

$$f_{\text{population}} = 1 - \prod_{j=1}^3 (1 - \varphi_j)^2 \quad (\text{III})$$

-wherein  $\varphi_j$  is the sum of frequencies in the population of allelic haplotypes encoding MHC molecules which bind any one of the T-cell epitopes in the vaccine and which belong to the  $j^{\text{th}}$  of the 3 known HLA loci (DP, DR and DQ); in practice, it is first determined which MHC molecules will recognize each T-cell epitope in the vaccine and thereafter these are listed by type (DP, DR and DQ) - then, the individual frequencies of the different listed allelic haplotypes are summed for each type, thereby yielding  $\varphi_1$ ,  $\varphi_2$ , and  $\varphi_3$ .

It may occur that the value  $p_i$  in formula II exceeds the corresponding theoretical value  $\pi_i$ :

$$\pi_i = 1 - \prod_{j=1}^3 (1 - \nu_j)^2 \quad (\text{IV})$$

-wherein  $\nu_j$  is the sum of frequencies in the population of allelic haplotype encoding MHC molecules which bind the  $i^{\text{th}}$  T-cell epitope in the vaccine and which belong to the  $j^{\text{th}}$  of the 3 known HLA loci (DP, DR and DQ). This means that in  $1 - \pi_i$  of

the population is a frequency of responders of  $f_{\text{residual}_i} = (p_i - \pi_i) / (1 - \pi_i)$ . Therefore, formula III can be adjusted so as to yield formula V:

$$f_{\text{population}} = 1 - \prod_{j=1}^3 (1 - \varphi_j)^2 + \left( 1 - \prod_{i=1}^n (1 - f_{\text{residual}_i}) \right) \quad (V)$$

5 -where the term  $1 - f_{\text{residual}_i}$  is set to zero if negative. It should be noted that formula V requires that all epitopes have been haplotype mapped against identical sets of haplotypes.

Therefore, when selecting T-cell epitopes to be introduced in the OPGL analogue, it is important to include all knowledge of  
10 the epitopes which is available: 1) The frequency of responders in the population to each epitope, 2) MHC restriction data, and 3) frequency in the population of the relevant haplotypes.

There exist a number of naturally occurring "promiscuous" T-  
15 cell epitopes which are active in a large proportion of individuals of an animal species or an animal population and these are preferably introduced in the vaccine thereby reducing the need for a very large number of different OPGL analogues in the same vaccine.

20 The promiscuous epitope can according to the invention be a naturally occurring human T-cell epitope such as epitopes from tetanus toxoid (e.g. the P2 and P30 epitopes), diphtheria toxoid, Influenza virus hemagglutinin (HA), and *P. falciparum* CS antigen.

25 Over the years a number of other promiscuous T-cell epitopes have been identified. Especially peptides capable of binding a large proportion of HLA-DR molecules encoded by the different HLA-DR alleles have been identified and these are all possible

T-cell epitopes to be introduced in the OPGL analogues used according to the present invention. Cf. also the epitopes discussed in the following references which are hereby all incorporated by reference herein: WO 98/23635 (Frazer IH et al., assigned to The University of Queensland); Southwood S et. al, 1998, J. Immunol. **160**: 3363-3373; Sinigaglia F et al., 1988, Nature **336**: 778-780; Chicz RM et al., 1993, J. Exp. Med **178**: 27-47; Hammer J et al., 1993, Cell **74**: 197-203; and Falk K et al., 1994, Immunogenetics **39**: 230-242. The latter reference also deals with HLA-DQ and -DP ligands. All epitopes listed in these 5 references are relevant as candidate natural epitopes to be used in the present invention, as are epitopes which share common motifs with these.

Alternatively, the epitope can be any artificial T-cell epitope which is capable of binding a large proportion of MHC Class II molecules. In this context the pan DR epitope peptides ("PADRE") described in WO 95/07707 and in the corresponding paper Alexander J et al., 1994, Immunity **1**: 751-761 (both disclosures are incorporated by reference herein) are interesting candidates for epitopes to be used according to the present invention. It should be noted that the most effective PADRE peptides disclosed in these papers carry D-amino acids in the C- and N-termini in order to improve stability when administered. However, the present invention primarily aims at incorporating the relevant epitopes as part of the modified OPGL which should then subsequently be broken down enzymatically inside the lysosomal compartment of APCs to allow subsequent presentation in the context of an MHC-II molecule and therefore it is not expedient to incorporate D-amino acids in the epitopes used in the present invention.

One especially preferred PADRE peptide is the one having the amino acid sequence AKFVAAWTLKAAA or an immunologically effective subsequence thereof. This, and other epitopes having the

same lack of MHC restriction are preferred T-cell epitopes which should be present in the OPGL analogues used in the inventive method. Such super-promiscuous epitopes will allow for the most simple embodiments of the invention wherein only  
5 one single modified OPGL is presented to the vaccinated animal's immune system.

As mentioned above, the modification of OPGL can also include the introduction of a first moiety which targets the modified OPGL to an APC or a B-lymphocyte. For instance, the first  
10 moiety can be a specific binding partner for a B-lymphocyte specific surface antigen or for an APC specific surface antigen. Many such specific surface antigens are known in the art. For instance, the moiety can be a carbohydrate for which there is a receptor on the B-lymphocyte or the APC (e.g. mannan or  
15 mannose). Alternatively, the second moiety can be a hapten. Also an antibody fragment which specifically recognizes a surface molecule on APCs or lymphocytes can be used as a first moiety (the surface molecule can e.g. be an FCγ receptor of macrophages and monocytes, such as FCγRI or, alternatively any  
20 other specific surface marker such as CD40 or CTLA-4). It should be noted that all these exemplary targeting molecules can be used as part of an adjuvant also, cf. below.

As an alternative or supplement to targeting the modified OPGL polypeptide to a certain cell type in order to achieve an enhanced immune response, it is possible to increase the level  
25 of responsiveness of the immune system by including the above-mentioned second moiety which stimulates the immune system. Typical examples of such second moieties are cytokines, and heat-shock proteins or molecular chaperones, as well as effective  
30 parts thereof.

Suitable cytokines to be used according to the invention are those which will normally also function as adjuvants in a vac-



cine composition, i.e. for instance interferon  $\gamma$  (IFN- $\gamma$ ), interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF); alternatively, the functional part of the cytokine molecule may suffice as the second moiety. With respect to the use of such cytokines as adjuvant substances, cf. the discussion below.

According to the invention, suitable heat-shock proteins or molecular chaperones used as the second moiety can be HSP70, HSP90, HSC70, GRP94 (also known as gp96, cf. Wearsch PA et al. 1998, Biochemistry 37: 5709-19), and CRT (calreticulin).

Alternatively, the second moiety can be a toxin, such as listeriolysin (LLO), lipid A and heat-labile enterotoxin. Also, a number of mycobacterial derivatives such as MDP (mureamyl dipeptide), CFA (complete Freund's adjuvant) and the trehalose diesters TDM and TDE are interesting possibilities.

Also the possibility of introducing a third moiety which enhances the presentation of the modified OPGL to the immune system is an important embodiment of the invention. The art has shown several examples of this principle. For instance, it is known that the palmitoyl lipidation anchor in the *Borrelia burgdorferi* protein OspA can be utilised so as to provide self-adjuvating polypeptides (cf. e.g. WO 96/40718) - it seems that the lipidated proteins form up micelle-like structures with a core consisting of the lipidation anchor parts of the polypeptides and the remaining parts of the molecule protruding therefrom, resulting in multiple presentations of the antigenic determinants. Hence, the use of this and related approaches using different lipidation anchors (e.g. a myristyl group, a myristyl group, a farnesyl group, a geranyl-geranyl group, a GPI-anchor, and an N-acyl diglyceride group) are

preferred embodiments of the invention, especially since the provision of such a lipidation anchor in a recombinantly produced protein is fairly straightforward and merely requires use of e.g. a naturally occurring signal sequence as a fusion partner for the modified OPGL polypeptide. Another possibility is use of the C3d fragment of complement factor C3 or C3 itself (cf. Dempsey et al., 1996, Science **271**, 348-350 and Lou & Kohler, 1998, Nature Biotechnology **16**, 458-462).

An alternative embodiment of the invention which also results in the preferred presentation of multiple (e.g. at least 2) copies of the important epitopic regions of OPGL to the immune system is the covalent coupling of OPGL, subsequence or variants thereof to certain molecules. For instance, polymers can be used, e.g. carbohydrates such as dextran, cf. e.g. Lees A et al., 1994, Vaccine **12**: 1160-1166; Lees A et al., 1990, J Immunol. **145**: 3594-3600, but also mannose and mannan are useful alternative. Integral membrane proteins from e.g. *E. coli* and other bacteria are also useful conjugation partners. The traditional carrier molecules such as keyhole limpet hemocyanin (KLH), tetanus toxoid, diphtheria toxoid, and bovine serum albumin (BSA) are also preferred and useful conjugation partners.

Certain areas of native OPGL seems to be most suited for performing modifications. Because of OPGL's structural relationship with TNF- $\alpha$  and other members of the tumour necrosis factor family, it is predicted that introductions of T-cell epitopes or other modifications in areas defined by positions 170-192, 198-218, 221-246, 256-261, or 285-316, (the amino acid numbering of SEQ ID NOs: 4, 6, and 12) will be most likely to produce the desired results. These positions refer to the murine OPGL - the corresponding positions in the human molecule are 171-193, 199-219, 222-247, 257-262, and 286-317 (the amino acid numbering of SEQ ID NO: 2).

Considerations underlying these chosen areas are a) preservation of known and predicted B-cell epitopes, b) preservation of tertiary structure etc. At any rate, as discussed above, it is fairly easy to screen a set of modified OPGL molecules which have all been subjected to introduction of a T-cell epitope in different locations.

Since the most preferred embodiments of the present invention involves down-regulation of human OPGL, it is consequently preferred that the OPGL polypeptide discussed above is a human OPGL polypeptide. In this embodiment, it is especially preferred that the human OPGL polypeptide has been modified by substituting at least one amino acid sequence in SEQ ID NO: 2 (or in a polypeptide where Cys-221 in SEQ ID NO: 2 has been substituted with serine) with at least one amino acid sequence of equal or different length and containing a foreign T<sub>H</sub> epitope. The substituted amino acid residues are selected from residues 257-262, 289-303 and 222-243 in SEQ ID NO: 2. The rationale behind such constructs is discussed in detail in the examples.

## 20 Formulation of OPGL and modified OPGL polypeptides

When effecting presentation of the OPGL polypeptide or the modified OPGL polypeptide to an animal's immune system by means of administration thereof to the animal, the formulation of the polypeptide follows the principles generally acknowledged in the art.

Preparation of vaccines which contain peptide sequences as active ingredients is generally well understood in the art, as exemplified by U.S. Patents 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all incorporated herein by reference. Typically, such vaccines are prepared as injectables either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior

to injection may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients  
5 are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the  
10 vaccines; cf. the detailed discussion of adjuvants below.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously, intracutaneously, intradermally, subdermally or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral, buccal,  
15 sublingual, intraperitoneal, intravaginal, anal, epidural, spinal, and intracranial formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may  
20 be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate,  
25 and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of active ingredient, preferably 25-70%. For oral formulations, cholera toxin is an interesting formulation partner (and also a possible  
30 conjugation partner).

The polypeptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the peptide) and which are formed with inorganic acids such as,

for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, 5 ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeuti- 10 cally effective and immunogenic. The quantity to be administered depends on the subject to be treated, including, e.g., the capacity of the individual's immune system to mount an immune response, and the degree of protection desired. Suitable dosage ranges are of the order of several hundred micro- 15 grams active ingredient per vaccination with a preferred range from about 0.1  $\mu\text{g}$  to 2,000  $\mu\text{g}$  (even though higher amounts in the 1-10 mg range are contemplated), such as in the range from about 0.5  $\mu\text{g}$  to 1,000  $\mu\text{g}$ , preferably in the range from 1  $\mu\text{g}$  to 500  $\mu\text{g}$  and especially in the range from about 10  $\mu\text{g}$  to 100  $\mu\text{g}$ . 20 Suitable regimens for initial administration and booster shots are also variable but are typified by an initial administration followed by subsequent inoculations or other administrations.

The manner of application may be varied widely. Any of the 25 conventional methods for administration of a vaccine are applicable. These include oral application on a solid physiologically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection or the like. The dosage of the vaccine will depend on the route of administration and 30 will vary according to the age of the person to be vaccinated and the formulation of the antigen.

Some of the polypeptides of the vaccine are sufficiently immunogenic in a vaccine, but for some of the others the

immune response will be enhanced if the vaccine further comprises an adjuvant substance.

Various methods of achieving adjuvant effect for the vaccine are known. General principles and methods are detailed in "The  
5 Theory and Practical Application of Adjuvants", 1995, Duncan-  
E.S. Stewart-Tull (ed.), John Wiley & Sons Ltd, ISBN 0-471-  
95170-6, and also in "Vaccines: New Generation Immunological  
Adjuvants", 1995, Gregoriadis G et al. (eds.), Plenum Press,  
New York, ISBN 0-306-45283-9, both of which are hereby incor-  
10 porated by reference herein.

It is especially preferred to use an adjuvant which can be demonstrated to facilitate breaking of the autotolerance to autoantigens; in fact, this is essential in cases where unmodified OPGL is used as the active ingredient in the autovac-  
15 cine. Non-limiting examples of suitable adjuvants are selected from the group consisting of an immune targeting adjuvant; an immune modulating adjuvant such as a toxin, a cytokine, and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating  
20 complex matrix (ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants;  $\gamma$ -inulin; and an encapsulating adjuvant. In general it should be noted that the disclosures above which relate to compounds and agents useful as first, second and third moieties in the analogues also refer *mutatis*  
25 *mutandis* to their use in the adjuvant of a vaccine of the invention.

The application of adjuvants include use of agents such as aluminum hydroxide or phosphate (alum), commonly used as 0.05 to 0.1 percent solution in buffered saline, admixture with  
30 synthetic polymers of sugars (e.g. Carbopol®) used as 0.25 percent solution, aggregation of the protein in the vaccine by heat treatment with temperatures ranging between 70° to 101°C

for 30 second to 2 minute periods respectively and also aggregation by means of cross-linking agents are possible. Aggregation by reactivation with pepsin treated antibodies (Fab fragments) to albumin, mixture with bacterial cells such as *C. parvum* or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed. Admixture with oils such as squalene and IFA is also preferred.

According to the invention DDA (dimethyldioctadecylammonium bromide) is an interesting candidate for an adjuvant as is DNA and  $\gamma$ -inulin, but also Freund's complete and incomplete adjuvants as well as *quillaja* saponins such as QuilA and QS21 are interesting as is RIBI. Further possibilities are monophosphoryl lipid A (MPL), the above mentioned C3 and C3d, and muramyl dipeptide (MDP).

Liposome formulations are also known to confer adjuvant effects, and therefore liposome adjuvants are preferred according to the invention.

Also immunostimulating complex matrix type (ISCOM® matrix) adjuvants are preferred choices according to the invention, especially since it has been shown that this type of adjuvants are capable of up-regulating MHC Class II expression by APCs. An ISCOM® matrix consists of (optionally fractionated) saponins (triterpenoids) from *Quillaja saponaria*, cholesterol, and phospholipid. When admixed with the immunogenic protein, the resulting particulate formulation is what is known as an ISCOM particle where the saponin constitutes 60-70% w/w, the cholesterol and phospholipid 10-15% w/w, and the protein 10-15% w/w. Details relating to composition and use of immunostimulating complexes can e.g. be found in the above-mentioned text-books

dealing with adjuvants, but also Morein B et al., 1995, Clin. Immunother. 3: 461-475 as well as Barr IG and Mitchell GF, 1996, Immunol. and Cell Biol. 74: 8-25 (both incorporated by reference herein) provide useful instructions for the preparation of complete immunostimulating complexes.

Another highly interesting (and thus, preferred) possibility of achieving adjuvant effect is to employ the technique described in Gosselin et al., 1992 (which is hereby incorporated by reference herein). In brief, the presentation of a relevant antigen such as an antigen of the present invention can be enhanced by conjugating the antigen to antibodies (or antigen binding antibody fragments) against the Fcγ receptors on monocytes/macrophages. Especially conjugates between antigen and anti-FcγRI have been demonstrated to enhance immunogenicity for the purposes of vaccination.

Other possibilities involve the use of the targeting and immune modulating substances (*i.a.* cytokines) mentioned above as candidates for the first and second moieties in the modified versions of OPGL. In this connection, also synthetic inducers of cytokines like poly I:C are possibilities.

Suitable mycobacterial derivatives are selected from the group consisting of muramyl dipeptide, complete Freund's adjuvant, RIBI, and a diester of trehalose such as TDM and TDE.

Suitable immune targeting adjuvants are selected from the group consisting of CD40 ligand and CD40 antibodies or specifically binding fragments thereof (*cf.* the discussion above), mannose, a Fab fragment, and CTLA-4.

Suitable polymer adjuvants are selected from the group consisting of a carbohydrate such as dextran, PEG, starch, man-



nan, and mannose; a plastic polymer such as; and latex such as latex beads.

Yet another interesting way of modulating an immune response is to include the OPGL immunogen (optionally together with  
5 adjuvants and pharmaceutically acceptable carriers and vehicles) in a "virtual lymph node" (VLN) (a proprietary medical device developed by ImmunoTherapy, Inc., 360 Lexington Avenue, New York, NY 10017-6501). The VLN (a thin tubular device) mimics the structure and function of a lymph node. Insertion  
10 of a VLN under the skin creates a site of sterile inflammation with an upsurge of cytokines and chemokines. T- and B-cells as well as APCs rapidly respond to the danger signals, home to the inflamed site and accumulate inside the porous matrix of the VLN. It has been shown that the necessary antigen dose  
15 required to mount an immune response to an antigen is reduced when using the VLN and that immune protection conferred by vaccination using a VLN surpassed conventional immunization using Ribi as an adjuvant. The technology is *i.a.* described briefly in Gelber C *et al.*, 1998, "Elicitation of Robust  
20 Cellular and Humoral Immune Responses to Small Amounts of Immunogens Using a Novel Medical Device Designated the Virtual Lymph Node", in: "From the Laboratory to the Clinic, Book of Abstracts, October 12<sup>th</sup> - 15<sup>th</sup> 1998, Seascape Resort, Aptos, California".

25 It is expected that the vaccine should be administered 1-6 times per year, such as 1, 2, 3, 4, 5, or 6 times a year to an individual in need thereof. It has previously been shown that the memory immunity induced by the use of the preferred autovaccines according to the invention is not permanent, and  
30 therefore the immune system needs to be periodically challenged with the OPGL or modified OPGL polypeptides.

Due to genetic variation, different individuals may react with immune responses of varying strength to the same polypeptide. Therefore, the vaccine according to the invention may comprise several different polypeptides in order to increase the immune response, cf. also the discussion above concerning the choice of foreign T-cell epitope introductions. The vaccine may comprise two or more polypeptides, where all of the polypeptides are as defined above.

The vaccine may consequently comprise 3-20 different modified or unmodified polypeptides, such as 3-10 different polypeptides.

#### Nucleic acid vaccination

As an alternative to classic administration of a peptide-based vaccine, the technology of nucleic acid vaccination (also known as "nucleic acid immunisation", "genetic immunisation", and "gene immunisation") offers a number of attractive features.

First, in contrast to the traditional vaccine approach, nucleic acid vaccination does not require resource consuming large-scale production of the immunogenic agent (e.g. in the form of industrial scale fermentation of microorganisms producing modified OPGL). Furthermore, there is no need to devise purification and refolding schemes for the immunogen. And finally, since nucleic acid vaccination relies on the biochemical apparatus of the vaccinated individual in order to produce the expression product of the nucleic acid introduced, the optimum posttranslational processing of the expression product is expected to occur; this is especially important in the case of autovaccination, since, as mentioned above, a significant fraction of the original OPGL B-cell epitopes should be preserved in the modified molecule, and since B-cell epitopes in principle can be constituted by parts of any

(bio)molecule (e.g. carbohydrate, lipid, protein etc.). Therefore, native glycosylation and lipidation patterns of the immunogen may very well be of importance for the overall immunogenicity and this is best ensured by having the host  
5 producing the immunogen.

Hence, a preferred embodiment of the invention comprises effecting presentation of modified OPGL to the immune system by introducing nucleic acid(s) encoding the modified OPGL into the animal's cells and thereby obtaining *in vivo* expression by  
10 the cells of the nucleic acid(s) introduced.

In this embodiment, the introduced nucleic acid is preferably DNA which can be in the form of naked DNA, DNA formulated with charged or uncharged lipids, DNA formulated in liposomes, DNA included in a viral vector, DNA formulated with a  
15 transfection-facilitating protein or polypeptide, DNA formulated with a targeting protein or polypeptide, DNA formulated with Calcium precipitating agents, DNA coupled to an inert carrier molecule, DNA encapsulated in chitin or chitosan, and DNA formulated with an adjuvant. In this context it is noted  
20 that practically all considerations pertaining to the use of adjuvants in traditional vaccine formulation apply for the formulation of DNA vaccines. Hence, all disclosures herein which relate to use of adjuvants in the context of polypeptide based vaccines apply *mutatis mutandis* to their use in nucleic  
25 acid vaccination technology.

As for routes of administration and administration schemes of polypeptide based vaccines which have been detailed above, these are also applicable for the nucleic acid vaccines of the invention and all discussions above pertaining to routes of  
30 administration and administration schemes for polypeptides apply *mutatis mutandis* to nucleic acids. To this should be added that nucleic acid vaccines can suitably be administered

intravenously and intraarterially. Furthermore, it is well-known in the art that nucleic acid vaccines can be administered by use of a so-called gene gun, and hence also this and equivalent modes of administration are regarded as part of the present invention. Finally, also the use of a VLN in the administration of nucleic acids has been reported to yield good results, and therefore this particular mode of administration is particularly preferred.

Furthermore, the nucleic acid(s) used as an immunization agent can contain regions encoding the 1<sup>st</sup>, 2<sup>nd</sup> and/or 3<sup>rd</sup> moieties, e.g. in the form of the immunomodulating substances described above such as the cytokines discussed as useful adjuvants. A preferred version of this embodiment encompasses having the coding region for the analogue and the coding region for the immunomodulator in different reading frames or at least under the control of different promoters. Thereby it is avoided that the analogue or epitope is produced as a fusion partner to the immunomodulator. Alternatively, two distinct nucleotide fragments can be used, but this is less preferred because of the advantage of ensured co-expression when having both coding regions included in the same molecule.

Accordingly, the invention also relates to a composition for inducing production of antibodies against OPGL, the composition comprising

- a nucleic acid fragment or a vector of the invention (cf. the discussion of vectors below), and
- a pharmaceutically and immunologically acceptable vehicle and/or carrier and/or adjuvant as discussed above.

Under normal circumstances, the OPGL variant-encoding nucleic acid is introduced in the form of a vector wherein expression is under control of a viral promoter. For more detailed discussions of vectors according to the invention, cf. the discussion below. Also, detailed disclosures relating to the

formulation and use of nucleic acid vaccines are available, cf. Donnelly JJ et al, 1997, Annu. Rev. Immunol. **15**: 617-648 and Donnelly JJ et al., 1997, Life Sciences **60**: 163-172. Both of these references are incorporated by reference herein.

## 5 Live vaccines

A third alternative for effecting presentation of modified OPGL to the immune system is the use of live vaccine technology. In live vaccination, presentation to the immune system is effected by administering, to the animal, a non-pathogenic  
10 microorganism which has been transformed with a nucleic acid fragment encoding a modified OPGL or with a vector incorporating such a nucleic acid fragment. The non-pathogenic microorganism can be any suitable attenuated bacterial strain (attenuated by means of passaging or by means of removal of patho-  
15 genic expression products by recombinant DNA technology), e.g. *Mycobacterium bovis* BCG., non-pathogenic *Streptococcus* spp., *E. coli*, *Salmonella* spp., *Vibrio cholerae*, *Shigella*, etc. Reviews dealing with preparation of state-of-the-art live vaccines can e.g. be found in Saliou P, 1995, Rev. Prat. **45**:  
20 1492-1496 and Walker PD, 1992, Vaccine **10**: 977-990, both incorporated by reference herein. For details about the nucleic acid fragments and vectors used in such live vaccines, cf. the discussion below.

As an alternative to bacterial live vaccines, the nucleic acid  
25 fragment of the invention discussed below can be incorporated in a non-virulent viral vaccine vector such as a vaccinia strain or any other suitable pox virus.

Normally, the non-pathogenic microorganism or virus is administered only once to the animal, but in certain cases it may  
30 be necessary to administer the microorganism more than once in a lifetime in order to maintain protective immunity. It is

even contemplated that immunization schemes as those detailed above for polypeptide vaccination will be useful when using live or virus vaccines.

Alternatively, live or virus vaccination is combined with  
5 previous or subsequent polypeptide and/or nucleic acid vaccination. For instance, it is possible to effect primary immunization with a live or virus vaccine followed by subsequent booster immunizations using the polypeptide or nucleic acid approach.

10 The microorganism or virus can be transformed with nucleic acid(s) containing regions encoding the 1<sup>st</sup>, 2<sup>nd</sup> and/or 3<sup>rd</sup> moieties, e.g. in the form of the immunomodulating substances described above such as the cytokines discussed as useful adjuvants. A preferred version of this embodiment encompasses  
15 having the coding region for the analogue and the coding region for the immunomodulator in different reading frames or at least under the control of different promoters. Thereby it is avoided that the analogue or epitopes are produced as fusion partners to the immunomodulator. Alternatively, two  
20 distinct nucleotide fragments can be used as transforming agents. Of course, having the 1<sup>st</sup> and/or 2<sup>nd</sup> and/or 3<sup>rd</sup> moieties in the same reading frame can provide as an expression product, an analogue of the invention, and such an embodiment is especially preferred according to the present invention.

## 25 Use of the method of the invention in disease treatment

As will be appreciated from the discussions above, the provision of the method of the invention allows for control of diseases characterized by excessive loss of bone mass. In this context, the disease osteoporosis is the key target for the  
30 inventive method but also bone loss associated with complicated bone fractures is a feasible target for treatment/ame-

lioration. Hence, an important embodiment of the method of the invention for down-regulating OPGL activity comprises treating and/or preventing and/or ameliorating osteoporosis or other conditions characterized by excess bone resorption, the method  
5 comprising down-regulating OPGL activity according to the method of the invention to such an extent that the rate of bone resorption is significantly decreased.

In the present context such a significant decrease in bone resorption is at least 3% compared to the pathological rate,  
10 but higher percentages are contemplated, such as at least 5%, at least 7%, at least 9%, at least 11%, at least 13%, at least 15%, and at least 17%, but even higher percentages are expected, such as at least 20%, or even at least 30%. It is especially preferred that the decrease in bone resorption  
15 results in an inversion of the balance between bone formation and bone resorption, i.e. that the rate of bone formation is brought to exceed the rate of bone resorption. Of course, this imbalance should not be maintained (since it would result in osteopetrosis), but by carefully controlling the number and  
20 immunological impact of immunizations of the individual in need thereof it is possible to obtain a balance over time which results in a net conservation of bone mass. Alternatively, if in an individual the method of the invention cannot terminate bone loss, the method of the invention can (option-  
25 ally in combination with other known methods for reducing bone loss in osteoporosis patients) be used to obtain a significant reduction in bone loss, thereby prolonging the time where sufficient bone mass is present in the individual.

Methods for measuring the rate of bone resorption and bone  
30 formation are known in the art. It is by means of biochemical assays possible to gauge the rate of bone resorption by measuring the blood concentration of certain fragments of collagen type I (cf. WO 93/15107 and WO 94/14844). Alterna-

tively, the rate of bone loss can be assessed by physical means; representative disclosures in the art of methods for assessing bone mass by non-invasive, physical methods can be found in WO 88/06862, WO 94/12855, WO 95/14431, and WO  
5 97/00643.

Peptides, polypeptides, and compositions of the invention

As will be apparent from the above, the present invention is based on the concept of immunising individuals against the OPGL antigen in order to indirectly obtain a reduced  
10 osteoclast activity. The preferred way of obtaining such an immunization is to use modified versions of OPGL, thereby providing molecules which have not previously been disclosed in the art.

It is believed that the modified OPGL molecules discussed  
15 herein are inventive in their own right, and therefore an important part of the invention pertains to an OPGL analogue which is derived from an animal OPGL wherein is introduced a modification which has as a result that immunization of the animal with the analogue induces production of antibodies  
20 reacting specifically with the unmodified OPGL polypeptide. Preferably, the nature of the modification conforms with the types of modifications described above when discussing various embodiments of the method of the invention when using modified OPGL. Hence, any disclosure presented herein pertaining to  
25 modified OPGL molecules are relevant for the purpose of describing the OPGL analogues of the invention, and any such disclosures apply *mutatis mutandis* to the description of these analogues.

It should be noted that preferred modified OPGL molecules com-  
30 prises modifications which results in a polypeptide having a sequence identity of at least 70% with OPGL or with a



subsequence thereof of at least 10 amino acids in length. Higher sequence identities are preferred, e.g. at least 75% or even at least 80, 85, 90, or 95%. The sequence identity for proteins and nucleic acids can be calculated as  $(N_{ref} - N_{dif}) \cdot 100 / N_{ref}$ , wherein  $N_{dif}$  is the total number of non-identical residues in the two sequences when aligned and wherein  $N_{ref}$  is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC will have a sequence identity of 75% with the sequence AATCAATC ( $N_{dif}=2$  and  $N_{ref}=8$ ).

10 The invention also pertains to compositions useful in exercising the method of the invention. Hence, the invention also relates to an immunogenic composition comprising an immunogenically effective amount of an OPGL polypeptide which is a self-protein in an animal, said OPGL polypeptide being  
15 formulated together with an immunologically acceptable adjuvant so as to break the animal's autotolerance towards the OPGL polypeptide, the composition further comprising a pharmaceutically and immunologically acceptable diluent and/or vehicle and/or carrier and/or excipient. In other words, this  
20 part of the invention pertains to the formulations of naturally occurring OPGL polypeptides which have been described in connection with embodiments of the method of the invention.

The invention also relates to an immunogenic composition comprising an immunologically effective amount of an OPGL  
25 analogue defined above, said composition further comprising a pharmaceutically and immunologically acceptable diluent and/or vehicle and/or carrier and/or excipient and optionally an adjuvant. In other words, this part of the invention concerns  
30 formulations of modified OPGL, essentially as described above. The choice of adjuvants, carriers, and vehicles is accordingly in line with what has been discussed above when referring to

formulation of modified and unmodified OPGL for use in the inventive method for the down-regulation of OPGL.

The polypeptides are prepared according to methods well-known in the art. Longer polypeptides are normally prepared by means of recombinant gene technology including introduction of a —  
5 nucleic acid sequence encoding the OPGL analogue into a suitable vector, transformation of a suitable host cell with the vector, expression of the nucleic acid sequence, recovery of the expression product from the host cells or their culture  
10 supernatant, and subsequent purification and optional further modification, e.g. refolding or derivatization.

Shorter peptides are preferably prepared by means of the well-known techniques of solid- or liquid-phase peptide synthesis. However, recent advances in this technology has rendered  
15 possible the production of full-length polypeptides and proteins by these means, and therefore it is also within the scope of the present invention to prepare the long constructs by synthetic means.

#### Nucleic acid fragments and vectors of the invention

20 It will be appreciated from the above disclosure that modified OPGL polypeptides can be prepared by means of recombinant gene technology but also by means of chemical synthesis or semisynthesis; the latter two options are especially relevant when the modification consists in coupling to protein carriers  
25 (such as KLH, diphtheria toxoid, tetanus toxoid, and BSA) and non-proteinaceous molecules such as carbohydrate polymers and of course also when the modification comprises addition of side chains or side groups to an OPGL polypeptide-derived peptide chain.

30 For the purpose of recombinant gene technology, and of course also for the purpose of nucleic acid immunization, nucleic

acid fragments encoding modified OPGL are important chemical products. Hence, an important part of the invention pertains to a nucleic acid fragment which encodes an OPGL analogue, *i.e.* an OPGL derived polypeptide which either comprises the  
5 natural OPGL sequence to which has been added or inserted a fusion partner or, preferably an OPGL derived polypeptide — wherein has been introduced a foreign T-cell epitope by means of insertion and/or addition, preferably by means of substitution and/or deletion. The nucleic acid fragments of the inven-  
10 tion are either DNA or RNA fragments.

The nucleic acid fragments of the invention will normally be inserted in suitable vectors to form cloning or expression vectors carrying the nucleic acid fragments of the invention; such novel vectors are also part of the invention. Details  
15 concerning the construction of these vectors of the invention will be discussed in context of transformed cells and microorganisms below. The vectors can, depending on purpose and type of application, be in the form of plasmids, phages, cosmids, mini-chromosomes, or virus, but also naked DNA which is only  
20 expressed transiently in certain cells is an important vector. Preferred cloning and expression vectors of the invention are capable of autonomous replication, thereby enabling high copy-numbers for the purposes of high-level expression or high-level replication for subsequent cloning.

25 The general outline of a vector of the invention comprises the following features in the 5'→3' direction and in operable linkage: a promoter for driving expression of the nucleic acid fragment of the invention, optionally a nucleic acid sequence encoding a leader peptide enabling secretion (to the  
30 extracellular phase or, where applicable, into the periplasma) of or integration into the membrane of the polypeptide fragment, the nucleic acid fragment of the invention, and optionally a nucleic acid sequence encoding a terminator. When

operating with expression vectors in producer strains or cell-lines it is for the purposes of genetic stability of the transformed cell preferred that the vector when introduced into a host cell is integrated in the host cell genome. In  
5 contrast, when working with vectors to be used for effecting *in vivo* expression in an animal (i.e. when using the vector in DNA vaccination) it is for security reasons preferred that the vector is incapable of being integrated in the host cell genome; typically, naked DNA or non-integrating viral vectors  
10 are used, the choices of which are well-known to the person skilled in the art

The vectors of the invention are used to transform host cells to produce the modified OPGL polypeptide of the invention. Such transformed cells, which are also part of the invention,  
15 can be cultured cells or cell lines used for propagation of the nucleic acid fragments and vectors of the invention, or used for recombinant production of the modified OPGL polypeptides of the invention. Alternatively, the transformed cells can be suitable live vaccine strains wherein the nucleic acid  
20 fragment (one single or multiple copies) have been inserted so as to effect secretion or integration into the bacterial membrane or cell-wall of the modified OPGL.

Preferred transformed cells of the invention are microorganisms such as bacteria (such as the species *Escherichia* [e.g.  
25 *E.coli*], *Bacillus* [e.g. *Bacillus subtilis*], *Salmonella*, or *Mycobacterium* [preferably non-pathogenic, e.g. *M. bovis* BCG]), yeasts (such as *Saccharomyces cerevisiae*), and protozoans. Alternatively, the transformed cells are derived from a multicellular organism such as a fungus, an insect cell, a  
30 plant cell, or a mammalian cell. Most preferred are cells derived from a human being, cf. the discussion of cell lines and vectors below. Recent results have shown great promise in the use of a commercially available *Drosophila melanogaster*

cell line (the Schneider 2 (S<sub>2</sub>) cell line and vector system available from Invitrogen) for the recombinant production of polypeptides in applicants' lab, and therefore this expression system is particularly preferred.

- 5 For the purposes of cloning and/or optimized expression it is preferred that the transformed cell is capable of replicating the nucleic acid fragment of the invention. Cells expressing the nucleic fragment are preferred useful embodiments of the invention; they can be used for small-scale or large-scale  
10 preparation of the modified OPGL or, in the case of non-pathogenic bacteria, as vaccine constituents in a live vaccine.

When producing the modified OPGL of the invention by means of transformed cells, it is convenient, although far from essential, that the expression product is either exported out into  
15 the culture medium or carried on the surface of the transformed cell.

When an effective producer cell has been identified it is preferred, on the basis thereof, to establish a stable cell line which carries the vector of the invention and which expresses  
20 the nucleic acid fragment encoding the modified OPGL. Preferably, this stable cell line secretes or carries the OPGL analogue of the invention, thereby facilitating purification thereof.

In general, plasmid vectors containing replicon and control  
25 sequences which are derived from species compatible with the host cell are used in connection with the hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, *E. coli* is typically trans-  
30 formed using pBR322, a plasmid derived from an *E. coli* species (see, e.g., Bolivar et al., 1977). The pBR322 plasmid contains

genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, promoters which can be used  
5 by the prokaryotic microorganism for expression.

Those promoters most commonly used in recombinant DNA construction include the B-lactamase (penicillinase) and lactose promoter systems (Chang et al., 1978; Itakura et al., 1977; Goeddel et al., 1979) and a tryptophan (trp) promoter system  
10 (Goeddel et al., 1979; EP-A-0 036 776). While these are the most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling a skilled worker to ligate them functionally with plasmid vectors (Siebwenlist et  
15 al., 1980). Certain genes from prokaryotes may be expressed efficiently in *E. coli* from their own promoter sequences, precluding the need for addition of another promoter by artificial means.

In addition to prokaryotes, eukaryotic microbes, such as yeast  
20 cultures may also be used, and here the promoter should be capable of driving expression. *Saccharomyces cerevisiae*, or common baker's yeast is the most commonly used among eukaryotic microorganisms, although a number of other strains are commonly available. For expression in *Saccharomyces*, the  
25 plasmid YRp7, for example, is commonly used (Stinchcomb et al., 1979; Kingsman et al., 1979; Tschemper et al., 1980). This plasmid already contains the *trp1* gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan for example ATCC No. 44076 or  
30 PEP4-1 (Jones, 1977). The presence of the *trp1* lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.

Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase (Hitzman et al., 1980) or other glycolytic enzymes (Hess et al., 1968; Holland et al., 1978), such as enolase, glyceraldehyde-3-phosphate  
5 dehydrogenase, hexokinase, pyruvate decarboxylase, phospho-  
fructokinase, glucose-6-phosphate isomerase, 3-phosphoglyce--  
rate mutase, pyruvate kinase, triosephosphate isomerase,  
phosphoglucose isomerase, and glucokinase. In constructing  
10 suitable expression plasmids, the termination sequences asso-  
ciated with these genes are also ligated into the expression  
vector 3' of the sequence desired to be expressed to provide  
polyadenylation of the mRNA and termination.

Other promoters, which have the additional advantage of tran-  
scription controlled by growth conditions are the promoter  
15 region for alcohol dehydrogenase 2, isocytochrome C, acid  
phosphatase, degradative enzymes associated with nitrogen  
metabolism, and the aforementioned glyceraldehyde-3-phosphate  
dehydrogenase, and enzymes responsible for maltose and  
galactose utilization. Any plasmid vector containing a yeast-  
20 compatible promoter, origin of replication and termination  
sequences is suitable.

In addition to microorganisms, cultures of cells derived from  
multicellular organisms may also be used as hosts. In princip-  
le, any such cell culture is workable, whether from vertebrate  
25 or invertebrate culture. However, interest has been greatest  
in vertebrate cells, and propagation of vertebrate in culture  
(tissue culture) has become a routine procedure in recent  
years (Tissue Culture, 1973). Examples of such useful host  
cell lines are VERO and HeLa cells, Chinese hamster ovary  
30 (CHO) cell lines, and W138, BHK, COS-7 293, *Spodoptera*  
*frugiperda* (SF) cells (commercially available as complete  
expression systems from i.a. Protein Sciences, 1000 Research  
Parkway, Meriden, CT 06450, U.S.A. and from Invitrogen), and

MDCK cell lines. In the present invention, an especially preferred cell line is S<sub>2</sub> available from Invitrogen, PO Box 2312, 9704 CH Groningen, The Netherlands.

Expression vectors for such cells ordinarily include (if  
5 necessary) an origin of replication, a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences.

For use in mammalian cells, the control functions on the  
10 expression vectors are often provided by viral material. For example, commonly used promoters are derived from polyoma, Adenovirus 2, and most frequently Simian Virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment  
15 which also contains the SV40 viral origin of replication (Fiers et al., 1978). Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the *Hind*III site toward the *Bgl*II site located in the viral origin of replication. Further, it  
20 is also possible, and often desirable, to utilize promoter or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell systems.

An origin of replication may be provided either by construc-  
25 tion of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.



Identification of useful OPGL analogues

It will be clear to the skilled person that not all possible variants or modifications of native OPGL will have the ability to elicit antibodies in an animal which are cross-reactive —  
5 with the native form. It is, however, not difficult to set up an effective standard screen for modified OPGL molecules which fulfill the minimum requirements for immunological reactivity discussed herein. Hence, another part of the invention concerns a method for the identification of a modified OPGL  
10 polypeptide which is capable of inducing antibodies against unmodified OPGL in an animal species where the unmodified OPGL polypeptide is a (non-immunogenic) self-protein, the method comprising

- 15 - preparing, by means of peptide synthesis or genetic engineering techniques, a set of mutually distinct modified OPGL polypeptides wherein amino acids have been added to, inserted in, deleted from, or substituted into the amino acid sequence of an OPGL polypeptide of the animal species thereby giving rise to amino acid sequences in the  
20 set which comprise T-cell epitopes which are foreign to the animal species, or preparing a set of nucleic acid fragments encoding the set of mutually distinct modified OPGL polypeptides,
- testing members of the set of modified OPGL polypeptides  
25 or nucleic acid fragments for their ability to induce production of antibodies by the animal species against the unmodified OPGL, and
- identifying and optionally isolating the member(s) of the  
30 set of modified OPGL polypeptides which significantly induces antibody production against unmodified OPGL in the species or identifying and optionally isolating the polypeptide expression products encoded by members of the set of nucleic acid fragments which significantly induces

antibody production against unmodified OPGL in the animal species.

In this context, the "set of mutually distinct modified OPGL polypeptides" is a collection of non-identical modified OPGL polypeptides which have e.g. been selected on the basis of the criteria discussed above (e.g. in combination with studies of circular dichroism, NMR spectra, and/or X-ray diffraction patterns). The set may consist of only a few members but it is contemplated that the set may contain several hundred members.

10 The test of members of the set can ultimately be performed *in vivo*, but a number of *in vitro* tests can be applied which narrow down the number of modified molecules which will serve the purpose of the invention.

Since the goal of introducing the foreign T-cell epitopes is to support the B-cell response by T-cell help, a prerequisite is that T-cell proliferation is induced by the modified OPGL. T-cell proliferation can be tested by standardized proliferation assays *in vitro*. In short, a sample enriched for T-cells is obtained from a subject and subsequently kept in culture.

20 The cultured T-cells are contacted with APCs of the subject which have previously taken up the modified molecule and processed it to present its T-cell epitopes. The proliferation of T-cells is monitored and compared to a suitable control (e.g. T-cells in culture contacted with APCs which have processed intact, native OPGL). Alternatively, proliferation can be measured by determining the concentration of relevant cytokines released by the T-cells in response to their recognition of foreign T-cells.

Having rendered highly probable that at least one modified OPGL of either type of set is capable of inducing antibody production against OPGL, it is possible to prepare an

immunogenic composition comprising at least one modified OPGL polypeptide which is capable of inducing antibodies against unmodified OPGL in an animal species where the unmodified OPGL polypeptide is a self-protein, the method comprising admixing  
5 the member(s) of the set which significantly induces production of antibodies in the animal species which are reactive with OPGL with a pharmaceutically and immunologically acceptable carrier and/or vehicle and/or diluent and/or excipient, optionally in combination with at least one pharmaceutically  
10 and immunologically acceptable adjuvant.

The above aspects of the invention pertaining to test of polypeptide sets are conveniently carried out by initially preparing a number of mutually distinct nucleic acid sequences or vectors of the invention, inserting these into appropriate  
15 expression vectors, transforming suitable host cells with the vectors, and expressing the nucleic acid sequences of the invention. These steps can be followed by isolation of the expression products. It is preferred that the nucleic acid sequences and/or vectors are prepared by methods comprising  
20 exercise of a molecular amplification technique such as PCR or by means of nucleic acid synthesis.

Another part of the invention concerns a method for the treatment, prophylaxis or amelioration of diseases characterized by excess bone resorption in an animal, including a human being,  
25 the method comprising administering, to the animal, an effective amount of at least one substance different from osteoprotegerin which blocks the stimulatory effect of OPGL on osteoclast activity. It is presently believed that such an approach has never been suggested in the art.

30 The preferred embodiment of this part of the invention involves use of an OPGL-specific antibody (poly- or monoclonal) or a specifically binding variant thereof as the substance blocking the stimulatory effect of OPGL. It is preferred that

the antibody is an IgG or IgM molecule, or that the specifically binding variant is derived from IgG or IgM. The specifically binding variant of the antibody can conveniently be a Fab fragment, a F(ab')<sub>2</sub> fragment, a humanized monoclonal antibody or fragment thereof, or a di- or multimeric antibody fragment such as a diabody (a bispecific and dimeric artificial antibody-derived molecule produced by Cambridge Antibody Technology).

#### EXAMPLE

10 It has been decided to clone or synthesize cDNAs encoding murine and human OPGL in the truncated version comprising amino acid residues 158-316 in the murine case and residues 159-317 in the human case (numbers correspond to the numbering in SEQ ID NOs: 2 and 4, respectively). As these truncated  
15 versions exhibit biological activity, it is logical to direct the autoantibodies against this part of OPGL. In addition, it makes the proteins smaller and thus easier to handle.

A synthetic cDNA encoding the murine OPGL residues 158-316 has been synthesized removing sub-optimal *Eschericia coli* and  
20 *Pichia pastoris* codons from the published sequence. Additionally, an N-terminal Histidine tag, part of the cleavage site of the alpha mating factor signal sequence from *Sacharomyces cerevisiae*, and suitable restriction enzymes have been incorporated into the open reading frame (cf. SEQ ID NO: 7).

25 This cDNA encoding wild type murine OPGL has been cloned into a standard *Eschericia coli* expression vector (pTrc99a) using *Bsp*HI and *Hind*III restriction enzymes and a standard cloning vector (pBluescript KS+) using *Sac*I and *Kpn*I restriction enzymes (yielding SEQ ID NO: 9).

Expression in *Eschericia coli* cells resulted in approximately 30% recombinant OPGL of the total *Eschericia coli* protein. The protein has been refolded and purified using the following procedure:

- 5 1. Cells are harvested by centrifugation.
2. Cells are resuspended in phosphate buffered saline (PBS) and recentrifuged.
3. The supernatant is discarded and the cells are resuspended in three volumes (100 mM Tris[hydroxymethyl]aminomethane hydrochloride, 5 mM dithiotreitol (DTT), 0.5 M NaCl, pH 8.0).
- 10 4. The cells are added 8  $\mu$ l 50 mM PMSF and 80  $\mu$ l lysozyme (10 mg/ml) per gram cell and incubated at room temperature for 20 min.
- 15 5. For each gram cell pellet, 4 mg deoxychloric acid is added, and the suspension is incubated at 37°C until it appears viscous.
6. 20  $\mu$ l DNase (1 mg/ml) pr. gram cell weight is added, and MgCl<sub>2</sub> to 5 mM, and the suspension is incubated at room temperature for 30 min.
- 20 7. The suspension is sonicated on ice until the viscosity disappears.
8. After centrifugation (20000 x g for 30 min) the pellet is resuspended in H<sub>2</sub>O, recentrifuged and resuspended in 3 ml 1 M urea per gram cell weight.
- 25 9. After centrifugation (20000 x g for 30 min) the pellet is resuspended in 1 M Guanidine hydrochloride, 100 mM Tris[hydroxymethyl]aminomethane hydrochloride, pH 7.5.
10. After centrifugation (20000 x g for 30 min) the pellet is resuspended in 6 M Guanidine hydrochloride, 20 mM Tris[hydroxymethyl]aminomethane hydrochloride, 5% ethanol, 1% beta-mercaptoethanol, pH 8.0, and stirred at 4°C overnight.
- 30

11. After centrifugation (40000 x g for 1-4 hours) the supernatant is filtered and stored at -20°C.
  12. The solubilized inclusion bodies are separated by gel filtration chromatography using Superdex 200 material (Pharmacia).
  13. The fractions containing the recombinant OPGL are pooled and diluted to 0.1 mg/ml with 1,5M Guanidine hydrochloride, 20 mM Tris[hydroxymethyl]aminomethane hydrochloride, 1 mM DTT, pH 7.5.
  - 10 14. The material is dialyzed overnight at 4°C against 10 volumes 1,5M Guanidine hydrochloride, 20 mM Tris[hydroxymethyl]aminomethane hydrochloride, 1 mM DTT, pH 7.5
  - 15 15. The material is dialyzed overnight at 4°C against 10 volumes 1,0 M Guanidine hydrochloride, 20 mM Tris[hydroxymethyl]aminomethane hydrochloride, 1 mM DTT, pH 7.5
  16. The material is dialyzed overnight at 4°C against 10 volumes 0,5 M Guanidine hydrochloride, 20 mM Tris[hydroxymethyl]aminomethane hydrochloride, 1 mM DTT, pH 7.5
  - 20 17. The material is dialyzed overnight at 4°C against 10 volumes 20 mM Tris[hydroxymethyl]aminomethane hydrochloride, 150 mM Arginine, 1 mM DTT, pH 7.5
  - 25 18. The material is dialyzed overnight at 4°C against 10 volumes 20 mM Tris[hydroxymethyl]aminomethane hydrochloride, 150 mM Arginine, pH 7.5
  19. The refolded material is freeze dried and stored at -20°C.
- 30 The efficiency of refolding using this procedure is approximately 40%, and the purity in excess of 65%. The purification procedure and refolding process are still subject to further improvements. Immobilized refolding are under investigation, and enzymatic removal of the Histidine-tag will

be performed essentially as described by Pedersen *et al.*, 1999. The nature of the recombinant protein has been characterized and verified using SDS-PAGE, N-terminal sequencing, amino acid analysis, and mass spectrometry.

- 5 A cysteine substitution mutant of the wild type murine OPGL is under construction (wherein a cysteine corresponding to amino acid residue in SEQ ID NO: 4 is substituted with serine; cf. SEQ ID NOS: 11 and 12). This is done to eliminate potential stability problems with the purified recombinant protein. This
- 10 mutated OPGL truncate will serve as basis for vaccine constructs in complete analogy with the description below which sets out from the DNA having SEQ ID NO: 9. Further, a corresponding Cys-Ser mutant (where Cys-221 is substituted) of human OPGL will also be produced for the same purposes.
- 15 The vaccine molecules are initially constructed by insertion or in-substitution of either the P2 or P30 epitope from tetanus toxoid at selected positions. Other suitable immunodominant T-cell epitopes may be used at a later stage.

The selected positions for the introduction of variation are

20 chosen based on knowledge of existing or predicted B-cell epitopes and predicted secondary structure elements of the native molecule, as well as using alignments with the existing three dimensional structures of TNF $\alpha$  (1a8m.pdb) and CD40 ligand (1aly.pdb) for modelling the secondary and tertiary

25 structure of the extracellular part of OPGL. The introduction in the murine molecule will take place in areas corresponding to amino acid residues 170-192, 198-218, 221-246, 256-261, and 285-316 (cf. the amino acid numbering in SEQ ID NO: 4), whereas the introduction in the human molecule will take place in

30 areas corresponding to amino acid residues 171-193, 199-219, 222-247, 257-262, and 286-317.

Four variants of murine OPGL have by now been constructed and expressed recombinantly in *Eschericia coli*:

DNA encoding mOPGL[158-316]\_P30[256-261] with an N-terminal Histidine tag (SEQ ID NO: 13):

5 PCR of SEQ ID NO: 9 was performed using SEQ ID NOs: 22 and 25 as primers. The resulting PCR fragment was restriction digested with *SacII* and *KpnI* and subsequently purified from an agarose gel. A second PCR using SEQ ID NO: 9 as template was performed using primer SEQ ID NO: 26 and a vector specific  
10 primer. The resulting PCR fragment was restriction digested with *KpnI* and *HindIII*. Both fragments were then ligated to SEQ ID NO: 9 in pBluescript KS+ restriction digested with *SacII* and *HindIII*. To correct a single base mutation in this construct, PCR using the construct as template was performed with  
15 primers SEQ ID NOs: 33 and 29. The resulting PCR fragment was restriction digested with *PstI* + *EcoRI*, gel purified and subsequently ligated to the erroneous construct digested with *PstI* and *EcoRI*. The verified construct (SEQ ID NO: 13) was then transferred to pTrc99a using *BspHI* and *HindIII* restriction  
20 enzymes.

DNA encoding mOPGL[158-316]\_P2[256-261] with an N-terminal Histidine tag (SEQ ID NO: 15):

PCR was performed using primers SEQ ID NOs: 27 and 28 without template. The resulting PCR fragment was restriction digested  
25 with *PstI* and *EcoRI* and subsequently purified from an agarose gel. The resulting fragment was then ligated to SEQ ID NO: 9 in pBluescript KS+ restriction digested with *SacII* and *HindIII*. The verified construct (SEQ ID NO: 15) was subsequently transferred to pTrc99a using *BspHI* and *HindIII*  
30 restriction enzymes

DNA encoding mOPGL[158-316]\_P2[288-302] with an N-terminal Histidine tag (SEQ ID NO: 17):



PCR of SEQ ID NO: 9 was performed using primers SEQ ID NOs: 22 and 29. The resulting PCR fragment was restriction digested with *Pst*I and *Bst*BI and subsequently purified from an agarose gel. A second PCR using SEQ ID NO: 9 as template was performed  
5 using primer SEQ ID NO: 30 and a vector specific primer. The resulting PCR fragment was restriction digested with *Bst*BI and *Kpn*I and subsequently gel purified. Both fragments were then ligated to SEQ ID NO: 9 in pBluescript KS+ restriction digested with *Pst*I and *Kpn*I. The verified construct (SEQ ID NO:  
10 17) was then transferred to pTrc99a using *Bsp*HI and *Hind*III restriction enzymes.

**DNA encoding mOPGL[158-316]\_P30[221-241] with an N-terminal Histidine tag (SEQ ID NO: 19):**

PCR of SEQ ID NO: 9 was performed using primers SEQ ID NOs: 22  
15 and 23. The resulting PCR fragment was restriction digested with *Sac*II and *Kpn*I and subsequently purified from an agarose gel. A second PCR using SEQ ID NO: 9 as template was performed using primer SEQ ID NOs: 24 and 31. The PCR fragment was restriction digested with *Kpn*I and *Eco*RI and subsequently gel  
20 purified. Both fragments were then ligated to SEQ ID NO: 9 in pBluescript KS+ restriction digested with *Sac*II and *Eco*RI. The verified construct (SEQ ID NO: 19) was then transferred to pTrc99a using *Bsp*HI and *Hind*III restriction enzymes.

Expression of these truncated variants of OPGL have taken  
25 place in *E. coli* yielding over 20% of total protein for all variants. A further development of the above-described purification and refolding procedure for the wild type protein (SEQ ID NO: 9) will be performed. This procedure will serve as a basis for the development of optimal procedures for each of  
30 the variants. Immobilized refolding of the variant proteins utilizing the Histidine tag is another approach that is being pursued.

Alternatively, the variants can be directly transferred to *Pichia pastoris* expression vectors using restriction enzymes, or other yeast expression systems using PCR if glycosylation is desired. It should be noted that the glycosylation is not  
5 needed for biological activity *in vivo* of OPGL. It is also possible to express the truncated OPGL in human 293 fibro- blasts as reported in Lacey *et al.* Expression in insect cells will also be considered (e.g. the Schneider 2 (S<sub>2</sub>) cell line and vector system or the *Spodoptera frugiperda* (SF) cell and  
10 vector systems, both available from Invitrogen).

The purified variants will be used for antibody production in rabbits for later use as detection tools as there exist no commercially available antibodies. In addition, this material will be a very valuable tool in the biological assays needed  
15 to evaluate the autovaccine candidates. The preparation of the antibodies will be performed using standard methods known in the art.

Selecting the best autovaccine candidate is based on assessment of inhibitory activity in *in vitro* assays for osteoclast  
20 maturation/activation or in *in vivo* animal models for osteoporosis. Useful assay and model systems are described in the literature (e.g. in Lacey *et al.*, Fuller *et al.*, and Simonet *et al.*).

The activity of the recombinant proteins will be analyzed by  
25 intravenous injection of 100 µl into un-anaesthetized male Balb/C mice (0, 0.1, and 1.0 mg protein pr. kg mouse) and one hour later withdrawal of 125 µl blood from the major eye vein using capillary tubes coated with calcium saturated heparin. The calcium levels are measured using an ICA2 (Radiometer,  
30 Denmark). Purified, and refolded recombinant murine OPGL (SEQ ID NO: 9) is reactive in this assay, increasing the circulating levels of ionized calcium by up to 10%.

The autovaccine candidates will e.g. be evaluated using autovaccination and subsequent monitoring of their inhibition of the release of ionized calcium to peripheral blood upon injection of recombinant mOPGL into mice (as described by  
5 Burgess et al.).

It should be noted that as an alternative to modified OPGL, antiidiotypic antibodies directed against the idiotype of an anti-OPGL antibody will also serve as useful immunogens within the scope of the present invention. Likewise, the use of  
10 mimotypic polypeptides which can be isolated in e.g. a phage display system using anti-OPGL or osteoprotegerin as catching probe are also considered as part of the immunogens of the invention.

#### LIST OF REFERENCES

- 15 1. Bucay, N. et al. (1998), Genes Dev. **12**, 1260-1268.
2. Lacey, D. L. et al. (1998), Cell **93**, 165-176.
3. Marks, S. C., Jr. (1989), Am. J. Med. Genet. **34**, 43-53.
4. Simonet, W. S. et al. (1997), Cell **89**, 309-319.
5. Fuller, K. et al. (1998), J. Exp. Med. **188**, 997-1001.
- 20 6. Burgess, T. L. et al. (1999), J. Cell Biol. **145**, 527-538.
7. Pedersen J et al. (1999) Protein Expr. Purif. **15**, 389-400.

## CLAIMS

1. A method for *in vivo* down-regulation of osteoprotegerin ligand (OPGL) activity in an animal, including a human being, the method comprising effecting presentation to the animal's  
5 immune system of an immunogenically effective amount of
- at least one OPGL polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the OPGL polypeptide or subsequence thereof induces production of antibodies against the OPGL  
10 polypeptide, and/or
  - at least one OPGL analogue wherein is introduced at least one modification in the OPGL amino acid sequence which has as a result that immunization of the animal with the analogue induces production of antibodies against the  
15 OPGL polypeptide.
2. The method according to claim 1, wherein is presented an OPGL analogue with at least one modification of the OPGL amino acid sequence.
3. The method according to claim 2, wherein the modification  
20 has as a result that a substantial fraction of OPGL B-cell epitopes are preserved and that
- at least one foreign T helper lymphocyte epitope ( $T_H$  epitope) is introduced, and/or
  - at least one first moiety is introduced which effects  
25 targeting of the modified molecule to an antigen presenting cell (APC) or a B-lymphocyte, and/or
  - at least one second moiety is introduced which stimulates the immune system, and/or
  - at least one third moiety is introduced which optimizes  
30 presentation of the modified OPGL polypeptide to the immune system.

4. The method according to claim 3, wherein the modification includes introduction as side groups, by covalent or non-covalent binding to suitable chemical groups in OPGL or a subsequence thereof, of the foreign T<sub>H</sub> epitope and/or of the first and/or of the second and/or of the third moiety.
5. The method according to claim 3 or 4, wherein the modification includes amino acid substitution and/or deletion and/or insertion and/or addition.
6. The method according to claim 5, wherein the modification results in the provision of a fusion polypeptide.
7. The method according to claim 5 or 6, wherein introduction of the amino acid substitution and/or deletion and/or insertion and/or addition results in a substantial preservation of the overall tertiary structure of OPGL.
8. The method according to any one of claims 2-7, wherein the modification includes duplication of at least one OPGL B-cell epitope and/or introduction of a hapten.
9. The method according to any one of claims 3-8, wherein the foreign T-cell epitope is immunodominant in the animal.
10. The method according to any one of claims 3-9, wherein the foreign T-cell epitope is promiscuous.
11. The method according to claim 10, wherein the at least one foreign T-cell epitope is selected from a natural promiscuous T-cell epitope and an artificial MHC-II binding peptide sequence.
12. The method according to claim 11, wherein the natural T-cell epitope is selected from a Tetanus toxoid epitope such as

P2 or P30, a diphtheria toxoid epitope, an influenza virus hemagglutinin epitope, and a *P. falciparum* CS epitope.

13. The method according to any one of claims 3-12, wherein the first moiety is a substantially specific binding partner  
5 for a B-lymphocyte specific surface antigen or for an APC specific surface antigen such as a hapten or a carbohydrate for which there is a receptor on the B-lymphocyte or the APC.

14. The method according to any one of claims 3-13, wherein the second moiety is selected from a cytokine, a hormone, and  
10 a heat-shock protein.

15. The method according to claim 6, wherein the cytokine is selected from, or is an effective part of, interferon  $\gamma$  (IFN- $\gamma$ ), Flt3L, interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12  
15 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF), and the heat-shock protein is selected from, or is an effective part of, HSP70, HSP90, HSC70, GRP94, and calreticulin (CRT).

16. The method according to any one of claims 3-15, wherein  
20 the third moiety is of lipid nature, such as a palmitoyl group, a myristyl group, a farnesyl group, a geranyl-geranyl group, a GPI-anchor, and an N-acyl diglyceride group.

17. The method according to any one of the preceding claims, wherein the OPGL polypeptide or subsequence thereof has been  
25 modified in any one of positions 170-192, any one of positions 198-218, any one of positions 221-246, any one of positions 256-261, or in any one of positions 285-316, the amino acid numbering conforming with that of any one of SEQ ID NOs: 4, 6, and 12, or wherein the OPGL polypeptide has been modified in  
30 any one of positions 171-193, any one of positions 199-219,

any one of positions 222-247, any one of positions 257-262, or in any one of positions 286-317, the amino acid numbering conforming with that of SEQ ID NO: 2.

18. The method according to claim 17, wherein the modification  
5 comprises a substitution of at least one amino acid sequence-  
within a position defined in claim 17 with an amino acid  
sequence of equal or different length which contains a foreign  
T<sub>H</sub> epitope.

19. The method according to claim 18, wherein the amino acid  
10 sequence containing the foreign T<sub>H</sub> epitope substitutes amino  
acids 256-261 and/or 288-302 and/or 221-241 found in SEQ ID  
NO: 4 or amino acids 257-262 and/or 289-303 and/or 222-243 in  
SEQ ID NO: 2 or in a polypeptide where a cysteine correspon-  
ding to Cys-221 has been substituted with Ser.

15 20. The method according to any one of the preceding claims,  
wherein presentation to the immune system is effected by  
having at least two copies of the OPGL polypeptide, the  
subsequence thereof or the modified OPGL polypeptide cova-  
lently or non-covalently linked to a carrier molecule capable  
20 of effecting presentation of multiple copies of antigenic  
determinants.

21. The method according to any the preceding claims, wherein  
the OPGL polypeptide, the subsequence thereof, or the modified  
OPGL polypeptide has been formulated with an adjuvant which  
25 facilitates breaking of autotolerance to autoantigens.

22. The method according to any one of the preceding claims,  
wherein an effective amount of the OPGL polypeptide or the  
OPGL analogue is administered to the animal via a route se-  
lected from the parenteral route such as the intradermal, the  
30 subdermal, the intracutaneous, the subcutaneous, and the  
intramuscular routes; the peritoneal route; the oral route;

the buccal route; the sublingual route; the epidural route; the spinal route; the anal route; and the intracranial route.

23. The method according to claim 22, wherein the effective amount is between 0.5 µg and 2,000 µg of the OPGL polypeptide, the subsequence thereof or the analogue thereof.

24. The method according to claim 22 or 23, wherein the OPGL polypeptide or analogue is contained in a virtual lymph node (VLN) device.

25. The method according to any one of claims 1-21, wherein presentation of modified OPGL to the immune system is effected by introducing nucleic acid(s) encoding the modified OPGL into the animal's cells and thereby obtaining *in vivo* expression by the cells of the nucleic acid(s) introduced.

26. The method according to claim 25, wherein the nucleic acid(s) introduced is/are selected from naked DNA, DNA formulated with charged or uncharged lipids, DNA formulated in liposomes, DNA included in a viral vector, DNA formulated with a transfection-facilitating protein or polypeptide, DNA formulated with a targeting protein or polypeptide, DNA formulated with Calcium precipitating agents, DNA coupled to an inert carrier molecule, DNA encapsulated in chitin or chitosan, and DNA formulated with an adjuvant.

27. The method according to claim 27, wherein the nucleic acid(s) is/are contained in a VLN device.

28. The method according to any one of claims 22-27, which includes at least one administration/introduction per year, such as at least 2, at least 3, at least 4, at least 6, and at least 12 administrations/introductions.



29. A method for treating and/or preventing and/or ameliorating osteoporosis or other diseases and conditions characterized by excess bone resorption, the method comprising down-regulating OPGL activity according to the method of any one of  
5 claims 1-28 to such an extent that the rate of bone resorption is significantly decreased, such as a decrease of at least 3%, at least 7%, at least 9%, at least 11%, at least 13%, at least 15%, at least 17%, at least 20%, and at least 30%.

30. An OPGL analogue which is derived from an animal OPGL  
10 polypeptide wherein is introduced a modification which has as a result that immunization of the animal with the analogue induces production of antibodies against the OPGL polypeptide.

31. An OPGL analogue according to claim 30, wherein the modification is as defined in any one of claims 1-19.

15 32. An immunogenic composition comprising

- an immunogenically effective amount of an OPGL polypeptide autologous in an animal, said OPGL polypeptide being formulated together with an immunologically acceptable adjuvant so as to break the animal's autotolerance to-  
20 wards the OPGL polypeptide, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle, or
- an immunogenically effective amount of an OPGL analogue according to claim 30 or 31, the composition further  
25 comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.

33. A nucleic acid fragment which encodes an OPGL analogue according to claim 30 or 31.

34. A vector carrying the nucleic acid fragment according to  
30 claim 33.

35. The vector according to claim 34 which is capable of autonomous replication.

36. The vector according to claim 34 or 35 which is selected from the group consisting of a plasmid, a phage, a cosmid, a mini-chromosome, and a virus.

37. The vector according to any one of claims 34-36, comprising, in the 5'-3' direction and in operable linkage, a promoter for driving expression of the nucleic acid fragment according to claim 33, optionally a nucleic acid sequence encoding a leader peptide enabling secretion of or integration into the membrane of the polypeptide fragment, the nucleic acid fragment according to claim 33, and optionally a terminator.

38. The vector according to any one of claims 34-37 which, when introduced into a host cell, is capable or incapable of being integrated in the host cell genome.

39. The vector according to claim 37 or 38, wherein a promoter drives expression in a eukaryotic cell and/or in a prokaryotic cell.

40. A transformed cell carrying the vector of any one of claims 34-39.

41. The transformed cell according to claim 40 which is capable of replicating the nucleic acid fragment according to claim 33.

42. The transformed cell according to claim 41, which is a microorganism selected from a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism selected from a fungus, an insect cell such as an S<sub>2</sub> or an SF cell, a plant cell, and a mammalian cell.

43. The transformed cell according to any one of claims 40-42, which expresses the nucleic acid fragment according to claim 33.

44. The transformed cell according to claim 43, which secretes or carries on its surface, the OPGL analogue according to claim 30 or 31.

45. The method according to any one of claims 1-19, wherein presentation to the immune system is effected by administering a non-pathogenic microorganism or virus which is carrying a nucleic acid fragment which encodes and expresses the OPGL polypeptide or analogue.

46. A composition for inducing production of antibodies against OPGL, the composition comprising

- a nucleic acid fragment according to claim 33 or a vector according to any one of claims 34-39, and
- a pharmaceutically and immunologically acceptable carrier and/or vehicle and/or adjuvant.

47. A stable cell line which carries the vector according to any one of claims 34-39 and which expresses the nucleic acid fragment according to claim 33, and which optionally secretes or carries the OPGL analogue according to claim 30 or 31 on its surface.

48. A method for the preparation of the cell according to any one of claims 40-44, the method comprising transforming a host cell with the nucleic acid fragment according to claim 33 or with the vector according to any one of claims 34-39.

49. A method for the identification of a modified OPGL polypeptide which is capable of inducing antibodies against unmodified OPGL in an animal species where the unmodified OPGL polypeptide is a self-protein, the method comprising

- preparing, by means of peptide synthesis or genetic engineering techniques, a set of mutually distinct modified OPGL polypeptides wherein amino acids have been added to, inserted in, deleted from, or substituted into the amino acid sequence of an OPGL polypeptide of the animal species thereby giving rise to amino acid sequences in the set which comprise T-cell epitopes which are foreign to the animal species, or preparing a set of nucleic acid fragments encoding the set of mutually distinct modified OPGL polypeptides,
- testing members of the set of modified OPGL polypeptides or nucleic acid fragments for their ability to induce production of antibodies by the animal species against the unmodified OPGL, and
- identifying and optionally isolating the member(s) of the set of modified OPGL polypeptides which significantly induces antibody production against unmodified OPGL in the species or identifying and optionally isolating the polypeptide expression products encoded by members of the set of nucleic acid fragments which significantly induces antibody production against unmodified OPGL in the animal species.

50. A method for the preparation of an immunogenic composition comprising at least one modified OPGL polypeptide which is capable of inducing antibodies against unmodified OPGL in an animal species where the unmodified OPGL polypeptide is a self-protein, the method comprising

- preparing, by means of peptide synthesis or genetic engineering techniques, a set of mutually distinct modified OPGL polypeptides wherein amino acids have been added to, inserted in, deleted from, or substituted into the amino acid sequence of an OPGL polypeptide of the animal species thereby giving rise to amino acid sequences in the

set comprising T-cell epitopes which are foreign to the animal,

- testing members of the set for their ability to induce production of antibodies by the animal species against the unmodified OPGL, and
- admixing the member(s) of the set which significantly induces production of antibodies in the animal species which are reactive with OPGL with a pharmaceutically and immunologically acceptable carrier and/or vehicle, optionally in combination with at least one pharmaceutically and immunologically acceptable adjuvant.

51. The method according to claim 49 or 50, wherein preparation of the members of the set comprises preparation of mutually distinct nucleic acid sequences, each sequence being a nucleic acid sequence according to claim 33, insertion of the nucleic acid sequences into appropriate expression vectors, transformation of suitable host cells with the vectors, and expression of the nucleic acid sequences, optionally followed by isolation of the expression products.

52. The method according to claim 51, wherein the preparation of the nucleic acid sequences and/or the vectors is achieved by the aid of a molecular amplification technique such as PCR or by the aid of nucleic acid synthesis.

53. Use of OPGL or a subsequence thereof for the preparation of an immunogenic composition comprising an adjuvant for down-regulating OPGL activity in an animal.

54. Use of OPGL or a subsequence thereof for the preparation of an immunogenic composition comprising an adjuvant for the treatment, prophylaxis or amelioration of osteoporosis or other conditions characterized by excessive bone resorption.

55. Use of an OPGL analogue for the preparation of an immunogenic composition optionally comprising an adjuvant for down-regulating OPGL activity in an animal.

56. Use of an OPGL analogue for the preparation of an immunogenic composition optionally comprising an adjuvant for the treatment, prophylaxis or amelioration of osteoporosis or other conditions characterized by excessive bone resorption.

## SEQUENCE LISTING

<110> M&E Biotech A/S  
 HALKIER, Torben  
 HAANING, Jesper

<120> Method for Down-Regulating Osteoprotegerin Ligand  
 Activity

<130> 22021 PC 1

<140>

<141>

<160> 35

<170> PatentIn Ver. 2.1

<210> 1

<211> 2271

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (185)..(1138)

<400> 1

```

aagcttggtta ccgagctcgg atccactact cgacccacgc gtccgcgcgc cccaggagcc 60
aaagccggggc tccaagtcgg cgccccacgt cgaggctccg ccgcagcctc cggagttggc 120
cgcagacaag aagggggaggg agcgggagag ggaggagagc tccgaagcga gagggcccgag 180
cgcc atg cgc cgc gcc agc aga gac tac acc aag tac ctg cgt ggc tcg 229
    Met Arg Arg Ala Ser Arg Asp Tyr Thr Lys Tyr Leu Arg Gly Ser
      1             5             10             15

gag gag atg ggc ggc ggc ccc gga gcc ccg cac gag ggc ccc ctg cac 277
Glu Glu Met Gly Gly Gly Pro Gly Ala Pro His Glu Gly Pro Leu His
      20             25             30

gcc ccg ccg ccg cct gcg ccg cac cag ccc ccc gcc gcc tcc cgc tcc 325
Ala Pro Pro Pro Pro Ala Pro His Gln Pro Pro Ala Ala Ser Arg Ser
      35             40             45

atg ttc gtg gcc ctc ctg ggg ctg ggg ctg ggc cag gtt gtc tgc agc 373
Met Phe Val Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys Ser
      50             55             60

```

gtc gcc ctg ttc ttc tat ttc aga gcg cag atg gat cct aat aga ata	421
Val Ala Leu Phe Phe Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg Ile	
65 70 75	
tca gaa gat ggc act cac tgc att tat aga att ttg aga ctc cat gaa	469
Ser Glu Asp Gly Thr His Cys Ile Tyr Arg Ile Leu Arg Leu His Glu	
80 85 90 95	
aat gca gat ttt caa gac aca act ctg gag agt caa gat aca aaa tta	517
Asn Ala Asp Phe Gln Asp Thr Thr Leu Glu Ser Gln Asp Thr Lys Leu	
100 105 110	
ata cct gat tca tgt agg aga att aaa cag gcc ttt caa gga gct gtg	565
Ile Pro Asp Ser Cys Arg Arg Ile Lys Gln Ala Phe Gln Gly Ala Val	
115 120 125	
caa aag gaa tta caa cat atc gtt gga tca cag cac atc aga gca gag	613
Gln Lys Glu Leu Gln His Ile Val Gly Ser Gln His Ile Arg Ala Glu	
130 135 140	
aaa gcg atg gtg gat ggc tca tgg tta gat ctg gcc aag agg agc aag	661
Lys Ala Met Val Asp Gly Ser Trp Leu Asp Leu Ala Lys Arg Ser Lys	
145 150 155	
ctt gaa gct cag cct ttt gct cat ctc act att aat gcc acc gac atc	709
Leu Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Thr Asp Ile	
160 165 170 175	
cca tct ggt tcc cat aaa gtg agt ctg tcc tct tgg tac cat gat cgg	757
Pro Ser Gly Ser His Lys Val Ser Leu Ser Ser Trp Tyr His Asp Arg	
180 185 190	
ggt tgg gcc aag atc tcc aac atg act ttt agc aat gga aaa cta ata	805
Gly Trp Ala Lys Ile Ser Asn Met Thr Phe Ser Asn Gly Lys Leu Ile	
195 200 205	
gtt aat cag gat ggc ttt tat tac ctg tat gcc aac att tgc ttt cga	853
Val Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg	
210 215 220	
cat cat gaa act tca gga gac cta gct aca gag tat ctt caa cta atg	901
His His Glu Thr Ser Gly Asp Leu Ala Thr Glu Tyr Leu Gln Leu Met	
225 230 235	
gtg tac gtc act aaa acc agc atc aaa atc cca agt tct cat acc ctg	949
Val Tyr Val Thr Lys Thr Ser Ile Lys Ile Pro Ser Ser His Thr Leu	
240 245 250 255	
atg aaa gga gga agc acc aag tat tgg tca ggg aat tct gaa ttc cat	997
Met Lys Gly Gly Ser Thr Lys Tyr Trp Ser Gly Asn Ser Glu Phe His	
260 265 270	



ttt tat tcc ata aac gtt ggt gga ttt ttt aag tta cgg tct gga gag 1045  
 Phe Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ser Gly Glu  
 275 280 285

gaa atc agc atc gag gtc tcc aac ccc tcc tta ctg gat ccg gat cag 1093  
 Glu Ile Ser Ile Glu Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln  
 290 295 300

gat gca aca tac ttt ggg gct ttt aaa gtt cga gat ata gat tga 1138  
 Asp Ala Thr Tyr Phe Gly Ala Phe Lys Val Arg Asp Ile Asp  
 305 310 315

gccccagttt ttggagtgtt atgtatttcc tggatgtttg gaaacatttt ttaaaacaag 1198  
 ccaagaaaga tgtatatagg tgtgtgagac tactaagagg catggcccca acggtacacg 1258  
 actcagtatc catgctcttg accttgtaga gaacacgcgt atttacagcc agtgggagat 1318  
 gttagactca tgggtgtgta cacaatgggt tttaaatttt gtaatgaatt cctagaatta 1378  
 aaccagattg gagcaattac gggttgacct tatgagaaac tgcattgtgg ctatgggagg 1438  
 ggttggtccc tggatcatgtg ccccttcgca gctgaagtgg agagggtgtc atctagcgca 1498  
 attgaaggat catctgaagg ggcaaattct tttgaattgt tacatcatgc tggaacctgc 1558  
 aaaaaatact ttttctaata aggagagaaa atatatgtat ttttatataa tatctaaagt 1618  
 tatatttcag atgtaatgtt ttctttgcaa agtattgtaa attatatttg tgctatagta 1678  
 tttgattcaa aatatttaaa aatgtcttgc tgttgacata ttaattgttt taaatgtaca 1738  
 gacatattta actggtgcac tttgtaaatt ccctggggaa aacttgcagc taaggagggg 1798  
 aaaaaaatgt tgtttcctaa tatcaaagc agtatatttc ttcgttcttt ttaagttaat 1858  
 agattttttc agacttgtca agcctgtgca aaaaaattaa aatggatgcc ttgaataata 1918  
 agcaggatgt tggccaccag gtgcctttca aatttagaaa ctaattgact ttagaaagct 1978  
 gacattgcca aaaaggatac ataatgggcc actgaaatct gtcaagagta gttatataat 2038  
 tgttgaacag gtgtttttcc acaagtgccg caaattgtac cttttttttt ttttcaaaat 2098  
 agaaaagtta ttagtggttt atcagcaaaa aagtccaatt ttaatttagt aaatgttatc 2158  
 ttatactgta caataaaaac attgcctttg aatgttaatt ttttgggtaca aaaataaatt 2218  
 tatatgaaaa aaaaaaaaaa agggcgggcg ctctagaggg ccctattcta tag 2271

&lt;210&gt; 2

&lt;211&gt; 317

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Arg Arg Ala Ser Arg Asp Tyr Thr Lys Tyr Leu Arg Gly Ser Glu
 1           5           10           15

Glu Met Gly Gly Gly Pro Gly Ala Pro His Glu Gly Pro Leu His Ala
      20           25           30

Pro Pro Pro Pro Ala Pro His Gln Pro Pro Ala Ala Ser Arg Ser Met
      35           40           45

Phe Val Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys Ser Val
      50           55           60

Ala Leu Phe Phe Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg Ile Ser
      65           70           75           80

Glu Asp Gly Thr His Cys Ile Tyr Arg Ile Leu Arg Leu His Glu Asn
      85           90           95

Ala Asp Phe Gln Asp Thr Thr Leu Glu Ser Gln Asp Thr Lys Leu Ile
      100          105          110

Pro Asp Ser Cys Arg Arg Ile Lys Gln Ala Phe Gln Gly Ala Val Gln
      115          120          125

Lys Glu Leu Gln His Ile Val Gly Ser Gln His Ile Arg Ala Glu Lys
      130          135          140

Ala Met Val Asp Gly Ser Trp Leu Asp Leu Ala Lys Arg Ser Lys Leu
      145          150          155          160

Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Thr Asp Ile Pro
      165          170          175

Ser Gly Ser His Lys Val Ser Leu Ser Ser Trp Tyr His Asp Arg Gly
      180          185          190

Trp Ala Lys Ile Ser Asn Met Thr Phe Ser Asn Gly Lys Leu Ile Val
      195          200          205

Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His
      210          215          220

His Glu Thr Ser Gly Asp Leu Ala Thr Glu Tyr Leu Gln Leu Met Val
      225          230          235          240

Tyr Val Thr Lys Thr Ser Ile Lys Ile Pro Ser Ser His Thr Leu Met
      245          250          255

Lys Gly Gly Ser Thr Lys Tyr Trp Ser Gly Asn Ser Glu Phe His Phe

```

260							265					270				
Tyr	Ser	Ile	Asn	Val	Gly	Gly	Phe	Phe	Lys	Leu	Arg	Ser	Gly	Glu	Glu	
275							280					285				
Ile	Ser	Ile	Glu	Val	Ser	Asn	Pro	Ser	Leu	Leu	Asp	Pro	Asp	Gln	Asp	
290							295					300				
Ala	Thr	Tyr	Phe	Gly	Ala	Phe	Lys	Val	Arg	Asp	Ile	Asp				
305					310		315									

```
<210> 3
<211> 951
<212> DNA
<213> Mus musculus
```

```
<220>  
<221> CDS  
<222> (1)..(951)
```

```
<220>
<221> misc_feature
<222> (142)..(213)
<223> Transmembrane domain
```

```
<220>
<221> misc_feature
<222> (454)..(948)
<223> Tumour Necrosis Factor(TNF)-like domain
```

```
<400> 3
atg cgc cgg gcc agc cga gac tac ggc aag tac ctg cgc agc tcg gag      48
Met Arg Arg Ala Ser Arg Asp Tyr Gly Lys Tyr Leu Arg Ser Ser Glu
      1           5           10           15
```

gag atg ggc agc ggc ccc ggc gtc cca cac gag ggt ccg ctg cac ccc 96  
Glu Met Gly Ser Gly Pro Gly Val Pro His Glu Gly Pro Leu His Pro  
20 25 30

gcg cct tct gca ccg gct ccg gcg ccg cca ccc gcc gcc tcc cgc tcc 144  
Ala Pro Ser Ala Pro Ala Pro Ala Pro Pro Pro Ala Ala Ser Arg Ser  
35 40 45

atg ttc ctg gcc ctc ctg ggg ctg gga ctg ggc cag gtg gtc tgc agc 192  
Met Phe Leu Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys Ser  
50 55 60

atc gct ctg ttc ctg tac ttt cga gcg cag atg gat cct aac aga ata 240  
Ile Ala Leu Phe Leu Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg Ile  
65 70 75 80

tca gaa gac agc act cac tgc ttt tat aga atc ctg aga ctc cat gaa	288
Ser Glu Asp Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu His Glu	
85 90 95	
aac gca ggt ttg cag gac tcg act ctg gag agt gaa gac aca cta cct	336
Asn Ala Gly Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr Leu Pro	
100 105 110	
gac tcc tgc agg agg atg aaa caa gcc ttt cag ggg gcc gtg cag aag	384
Asp Ser Cys Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val Gln Lys	
115 120 125	
gaa ctg caa cac att gtg ggg cca cag cgc ttc tca gga gct cca gct	432
Glu Leu Gln His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala Pro Ala	
130 135 140	
atg atg gaa ggc tca tgg ttg gat gtg gcc cag cga ggc aag cct gag	480
Met Met Glu Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys Pro Glu	
145 150 155 160	
gcc cag cca ttt gca cac ctc acc atc aat gct gcc agc atc cca tcg	528
Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro Ser	
165 170 175	
ggt tcc cat aaa gtc act ctg tcc tct tgg tac cac gat cga ggc tgg	576
Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly Trp	
180 185 190	
gcc aag atc tct aac atg acg tta agc aac gga aaa cta agg gtt aac	624
Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val Asn	
195 200 205	
caa gat ggc ttc tat tac ctg tac gcc aac att tgc ttt cgg cat cat	672
Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His His	
210 215 220	
gaa aca tcg gga agc gta cct aca gac tat ctt cag ctg atg gtg tat	720
Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val Tyr	
225 230 235 240	
gtc gtt aaa acc agc atc aaa atc cca agt tct cat aac ctg atg aaa	768
Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met Lys	
245 250 255	
gga ggg agc acg aaa aac tgg tcg ggc aat tct gaa ttc cac ttt tat	816
Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr	
260 265 270	
tcc ata aat gtt ggg gga ttt ttc aag ctc cga gct ggt gaa gaa att	864
Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile	
275 280 285	

agc att cag gtg tcc aac cct tcc ctg ctg gat ccg gat caa gat gcg 912  
 Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala  
 290 295 300

acg tac ttt ggg gct ttc aaa gtt cag gac ata gac tga 951  
 Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
 305 310 315

<210> 4

<211> 316

<212> PRT

<213> Mus musculus

<400> 4

Met Arg Arg Ala Ser Arg Asp Tyr Gly Lys Tyr Leu Arg Ser Ser Glu  
 1 5 10 15

Glu Met Gly Ser Gly Pro Gly Val Pro His Glu Gly Pro Leu His Pro  
 20 25 30

Ala Pro Ser Ala Pro Ala Pro Ala Pro Pro Ala Ala Ser Arg Ser  
 35 40 45

Met Phe Leu Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys Ser  
 50 55 60

Ile Ala Leu Phe Leu Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg Ile  
 65 70 75 80

Ser Glu Asp Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu His Glu  
 85 90 95

Asn Ala Gly Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr Leu Pro  
 100 105 110

Asp Ser Cys Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val Gln Lys  
 115 120 125

Glu Leu Gln His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala Pro Ala  
 130 135 140

Met Met Glu Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys Pro Glu  
 145 150 155 160

Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro Ser  
 165 170 175

Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly Trp  
 180 185 190

Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val Asn  
 195 200 205

Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His His  
 210 215 220

Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val Tyr  
 225 230 235 240

Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met Lys  
 245 250 255

Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr  
 260 265 270

Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile  
 275 280 285

Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala  
 290 295 300

Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
 305 310 315

<210> 5

<211> 2299

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (170)..(1120)

<400> 5

gagctcggat ccactactcg acccacgcgt ccgcccacgc gtccggccag gacctctgtg 60

aaccggtcgg ggcgggggcc gcctggccgg gagtctgctc ggcggtgggt ggccgaggaa 120

gggagagaac gatcgcgagg cagggcgccc gaactccggg cgccgcgcc atg cgc cgg 178  
 Met Arg Arg  
 1

gcc agc cga gac tac ggc aag tac ctg cgc agc tcg gag gag atg ggc 226  
 Ala Ser Arg Asp Tyr Gly Lys Tyr Leu Arg Ser Ser Glu Glu Met Gly  
 5 10 15

agc ggc ccc ggc gtc cca cac gag ggt ccg ctg cac ccc gcg cct tct 274  
 Ser Gly Pro Gly Val Pro His Glu Gly Pro Leu His Pro Ala Pro Ser  
 20 25 30 35

gca ccg gct ccg gcg ccg cca ccc gcc gcc tcc cgc tcc atg ttc ctg 322  
 Ala Pro Ala Pro Ala Pro Pro Pro Ala Ala Ser Arg Ser Met Phe Leu  
 40 45 50

gcc ctc ctg ggg ctg gga ctg ggc cag gtg gtc tgc agc atc gct ctg	370
Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys Ser Ile Ala Leu	
55 60 65	
ttc ctg tac ttt cga gcg cag atg gat cct aac aga ata tca gaa gac	418
Phe Leu Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg Ile Ser Glu Asp	
70 75 80	
agc act cac tgc ttt tat aga atc ctg aga ctc cat gaa aac gca ggt	466
Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu His Glu Asn Ala Gly	
85 90 95	
ttg cag gac tcg act ctg gag agt gaa gac aca cta cct gac tcc tgc	514
Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr Leu Pro Asp Ser Cys	
100 105 110 115	
agg agg atg aaa caa gcc ttt cag ggg gcc gtg cag aag gaa ctg caa	562
Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val Gln Lys Glu Leu Gln	
120 125 130	
cac att gtg ggg cca cag cgc ttc tca gga gct cca gct atg atg gaa	610
His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala Pro Ala Met Met Glu	
135 140 145	
ggc tca tgg ttg gat gtg gcc cag cga ggc aag cct gag gcc cag cca	658
Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys Pro Glu Ala Gln Pro	
150 155 160	
ttt gca cac ctc acc atc aat gct gcc agc atc cca tcg ggt tcc cat	706
Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro Ser Gly Ser His	
165 170 175	
aaa gtc act ctg tcc tct tgg tac cac gat cga ggc tgg gcc aag atc	754
Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly Trp Ala Lys Ile	
180 185 190 195	
tct aac atg acg tta agc aac gga aaa cta agg gtt aac caa gat ggc	802
Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val Asn Gln Asp Gly	
200 205 210	
ttc tat tac ctg tac gcc aac att tgc ttt cgg cat cat gaa aca tcg	850
Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His His Glu Thr Ser	
215 220 225	
gga agc gta cct aca gac tat ctt cag ctg atg gtg tat gtc gtt aaa	898
Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val Tyr Val Val Lys	
230 235 240	
acc agc atc aaa atc cca agt tct cat aac ctg atg aaa gga ggg agc	946
Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met Lys Gly Gly Ser	
245 250 255	

```

acg aaa aac tgg tcg ggc aat tct gaa ttc cac ttt tat tcc ata aat 994
Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr Ser Ile Asn
260                265                270                275

ggt ggg gga ttt ttc aag ctc cga gct ggt gaa gaa att agc att cag 1042
Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile Ser Ile Gln
                280                285                290

gtg tcc aac cct tcc ctg ctg gat ccg gat caa gat gcg acg tac ttt 1090
Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr Tyr Phe
                295                300                305

ggg gct ttc aaa gtt cag gac ata gac tga gactcatttc gtggaacatt 1140
Gly Ala Phe Lys Val Gln Asp Ile Asp
                310                315

agcatggatg tcctagatgt ttggaaaactt cttaaaaaaat ggatgatgtc tatacatgtg 1200

taagactact aagagacatg gccacggtg tatgaaactc acagccctct ctcttgagcc 1260

tgtacagggt gtgtatatgt aaagtccata ggtgatgtta gattcatggt gattacacaa 1320

cggttttaca attttgtaat gatttcctag aattgaacca gattgggaga ggtattccga 1380

tgcttatgaa aaacttacac gtgagctatg gaagggggtc acagtctctg ggtctaacc 1440

ctggacatgt gccactgaga accttgaaat taagaggatg ccatgtcatt gcaaagaaat 1500

gatagtgtga agggttaagt tcttttgaat tgttacattg cgctgggacc tgcaaataag 1560

ttcttttttt ctaatgagga gagaaaaata tatgtatttt tatataatgt ctaaagttat 1620

atttcagggtg taatgttttc tgtgcaaagt tttgtaaatt atatttgtgc tatagtattt 1680

gattcaaaat atttaaaaat gtctcactgt tgacatatatt aatgttttaa atgtacagat 1740

gtatttaact ggtgcacttt gtaattcccc tgaagggtact cgtagctaag ggggcagaat 1800

actgtttctg gtgaccacat gtagtttatt tctttattct ttttaactta atagagtctt 1860

cagacttgtc aaaactatgc aagcaaaata aataaataaa aataaaatga ataccttgaa 1920

taataagtag gatgttggtc accagggtgcc tttcaaattt agaagctaatt tgactttagg 1980

agctgacata gccaaaaagg atacataata ggctactgaa atctgtcagg agtatttatg 2040

caattattga acagggtgtc ttttttaca gagctacaaa ttgtaaattt tgtttctttt 2100

ttttcccata gaaaatgtac tatagtttat cagccaaaaa acaatccact ttttaattta 2160

gtgaaagtta ttttattata ctgtacaata aaagcattgt ctctgaatgt taattttttg 2220

gtacaaaaaa taaatttgta cgaaaacctg aaaaaaaaaa aaaaaaaggg cggccgctct 2280

```



agagggccct attctatag

2299

&lt;210&gt; 6

&lt;211&gt; 316

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 6

Met Arg Arg Ala Ser Arg Asp Tyr Gly Lys Tyr Leu Arg Ser Ser Glu  
 1 5 10 15

Glu Met Gly Ser Gly Pro Gly Val Pro His Glu Gly Pro Leu His Pro  
 20 25 30

Ala Pro Ser Ala Pro Ala Pro Ala Pro Pro Ala Ala Ser Arg Ser  
 35 40 45

Met Phe Leu Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys Ser  
 50 55 60

Ile Ala Leu Phe Leu Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg Ile  
 65 70 75 80

Ser Glu Asp Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu His Glu  
 85 90 95

Asn Ala Gly Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr Leu Pro  
 100 105 110

Asp Ser Cys Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val Gln Lys  
 115 120 125

Glu Leu Gln His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala Pro Ala  
 130 135 140

Met Met Glu Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys Pro Glu  
 145 150 155 160

Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro Ser  
 165 170 175

Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly Trp  
 180 185 190

Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val Asn  
 195 200 205

Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His His  
 210 215 220

Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val Tyr  
 225 230 235 240

12

Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met Lys  
 245 250 255

Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr  
 260 265 270

Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile  
 275 280 285

Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala  
 290 295 300

Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
 305 310 315

<210> 7

<211> 564

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(564)

<220>

<223> Description of Artificial Sequence: Synthetic PCR  
 product with optimum codons for E. coli and P.  
 pastoris expression

<220>

<221> misc\_binding

<222> (43)..(84)

<223> His tag

<220>

<221> misc\_feature

<222> (1)..(36)

<223> C-terminal part of *Saccharomyces cerevisiae*  
 alpha-mating factor

<220>

<221> misc\_feature

<222> (85)..(561)

<223> Encoding wild type murine OPGL, residues 158-316

<400> 7

gag ctc gga tcc ctc gag aaa aga gag gct gaa gct cat gtc atg aaa 48  
 Glu Leu Gly Ser Leu Glu Lys Arg Glu Ala Glu Ala His Val Met Lys  
 1 5 10 15

13

cac caa cac caa cat caa cat caa cat caa cat caa aaa cct gaa gct	96
His Gln His Gln His Gln His Gln His Gln His Gln Lys Pro Glu Ala	
20 25 30	
cag cca ttc gct cat ctg acc atc aac gct gca tcg atc cct tct ggt	144
Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro Ser Gly	
35 40 45	
tct cat aaa gtt acc ctg tct tct tgg tat cac gac cgc ggt tgg gct	192
Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly Trp Ala	
50 55 60	
aaa atc tct aac atg acc ctg tct aac ggt aaa ctg aga gtt aac cag	240
Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val Asn Gln	
65 70 75 80	
gac ggt ttc tac tac ctg tac gct aac atc tgt ttc aga cat cac gaa	288
Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His His Glu	
85 90 95	
acc tct ggt tct gtt cca acc gac tac ctg cag ctg atg gtt tac gtt	336
Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val Tyr Val	
100 105 110	
gtt aaa acc tct atc aaa atc cca tct tca cat aac ctg atg aaa ggt	384
Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met Lys Gly	
115 120 125	
ggt tct acc aaa aac tgg tct ggt aac tct gaa ttc cat ttc tac tct	432
Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr Ser	
130 135 140	
atc aac gtt ggt ggt ttc ttc aaa ctg aga gct ggt gaa gaa atc tct	480
Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile Ser	
145 150 155 160	
atc cag gtt tct aac cct tct ctg ctg gac cca gac cag gac gct acc	528
Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr	
165 170 175	
tac ttc ggg gcc ttc aaa gtt cag gac atc gac tag	564
Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp	
180 185	

&lt;210&gt; 8

&lt;211&gt; 187

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<223> Description of Artificial Sequence: Synthetic PCR product with optimum codons for E. coli and P. pastoris expression

14

&lt;400&gt; 8

Glu Leu Gly Ser Leu Glu Lys Arg Glu Ala Glu Ala His Val Met Lys  
 1 5 10 15

His Gln His Gln His Gln His Gln His Gln Lys Pro Glu Ala  
 20 25 30

Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro Ser Gly  
 35 40 45

Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly Trp Ala  
 50 55 60

Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val Asn Gln  
 65 70 75 80

Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His His Glu  
 85 90 95

Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val Tyr Val  
 100 105 110

Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met Lys Gly  
 115 120 125

Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr Ser  
 130 135 140

Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile Ser  
 145 150 155 160

Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr  
 165 170 175

Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
 180 185

&lt;210&gt; 9

&lt;211&gt; 519

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: DNA encoding  
 murine OPGL, residues 158-316, fused to His tag

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(519)

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; (1)..(42)

&lt;223&gt; His tag

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (43)..(519)

&lt;223&gt; Murine OPGL, residues 158-316

&lt;400&gt; 9

atg aaa cac caa cac caa cat caa cat caa cat caa cat caa aaa cct	48
Met Lys His Gln His Gln His Gln His Gln His Gln His Gln Lys Pro	
1 5 10 15	
 gaa gct cag cca ttc gct cat ctg acc atc aac gct gca tcg atc cct	96
Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro	
20 25 30	
 tct ggt tct cat aaa gtt acc ctg tct tct tgg tat cac gac cgc ggt	144
Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly	
35 40 45	
 tgg gct aaa atc tct aac atg acc ctg tct aac ggt aaa ctg aga gtt	192
Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val	
50 55 60	
 aac cag gac ggt ttc tac tac ctg tac gct aac atc tgt ttc aga cat	240
Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His	
65 70 75 80	
 cac gaa acc tct ggt tct gtt cca acc gac tac ctg cag ctg atg gtt	288
His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val	
85 90 95	
 tac gtt gtt aaa acc tct atc aaa atc cca tct tca cat aac ctg atg	336
Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met	
100 105 110	
 aaa ggt ggt tct acc aaa aac tgg tct ggt aac tct gaa ttc cat ttc	384
Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe	
115 120 125	
 tac tct atc aac gtt ggt ggt ttc ttc aaa ctg aga gct ggt gaa gaa	432
Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu	
130 135 140	
 atc tct atc cag gtt tct aac cct tct ctg ctg gac cca gac cag gac	480
Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp	
145 150 155 160	
 gct acc tac ttc ggg gcc ttc aaa gtt cag gac atc gac	519
Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp	
165 170	

&lt;210&gt; 10

&lt;211&gt; 173

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<223> Description of Artificial Sequence: DNA encoding  
murine OPGL, residues 158-316, fused to His tag

&lt;400&gt; 10

Met	Lys	His	Gln	His	Gln	His	Gln	His	Gln	His	Gln	His	Gln	Lys	Pro
1				5					10					15	

Glu	Ala	Gln	Pro	Phe	Ala	His	Leu	Thr	Ile	Asn	Ala	Ala	Ser	Ile	Pro
			20					25						30	

Ser	Gly	Ser	His	Lys	Val	Thr	Leu	Ser	Ser	Trp	Tyr	His	Asp	Arg	Gly
		35					40					45			

Trp	Ala	Lys	Ile	Ser	Asn	Met	Thr	Leu	Ser	Asn	Gly	Lys	Leu	Arg	Val
	50				55						60				

Asn	Gln	Asp	Gly	Phe	Tyr	Tyr	Leu	Tyr	Ala	Asn	Ile	Cys	Phe	Arg	His
65					70					75					80

His	Glu	Thr	Ser	Gly	Ser	Val	Pro	Thr	Asp	Tyr	Leu	Gln	Leu	Met	Val
				85					90					95	

Tyr	Val	Val	Lys	Thr	Ser	Ile	Lys	Ile	Pro	Ser	Ser	His	Asn	Leu	Met
			100					105					110		

Lys	Gly	Gly	Ser	Thr	Lys	Asn	Trp	Ser	Gly	Asn	Ser	Glu	Phe	His	Phe
		115					120					125			

Tyr	Ser	Ile	Asn	Val	Gly	Gly	Phe	Phe	Lys	Leu	Arg	Ala	Gly	Glu	Glu
	130					135					140				

Ile	Ser	Ile	Gln	Val	Ser	Asn	Pro	Ser	Leu	Leu	Asp	Pro	Asp	Gln	Asp
145					150					155					160

Ala	Thr	Tyr	Phe	Gly	Ala	Phe	Lys	Val	Gln	Asp	Ile	Asp
				165					170			

&lt;210&gt; 11

&lt;211&gt; 519

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Fusion of  
murine OPGL, residues 158-316 with C to S  
mutation, and His tag

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(519)

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; (1)..(42)

&lt;223&gt; His tag

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (43)..(228)

&lt;223&gt; Murine OPGL, residues 158-219

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (232)..(519)

&lt;223&gt; Murine OPGL, residues 221-316

&lt;220&gt;

&lt;221&gt; mutation

&lt;222&gt; (229)..(231)

&lt;223&gt; tgt (Cys) to tcc (Ser)

&lt;220&gt;

&lt;400&gt; 11

atg	aaa	cac	caa	cac	caa	cat	caa	cat	caa	cat	caa	aaa	cct	48
Met	Lys	His	Gln	His	Gln	His	Gln	His	Gln	His	Gln	Lys	Pro	
1				5				10				15		

gaa	gct	cag	cca	ttc	gct	cat	ctg	acc	atc	aac	gct	gca	tcg	atc	cct	96
Glu	Ala	Gln	Pro	Phe	Ala	His	Leu	Thr	Ile	Asn	Ala	Ala	Ser	Ile	Pro	
			20				25					30				

tct	ggt	tct	cat	aaa	ggt	acc	ctg	tct	tct	tgg	tat	cac	gac	cgc	ggt	144
Ser	Gly	Ser	His	Lys	Val	Thr	Leu	Ser	Ser	Trp	Tyr	His	Asp	Arg	Gly	
		35					40					45				

tgg	gct	aaa	atc	tct	aac	atg	acc	ctg	tct	aac	ggt	aaa	ctg	aga	ggt	192
Trp	Ala	Lys	Ile	Ser	Asn	Met	Thr	Leu	Ser	Asn	Gly	Lys	Leu	Arg	Val	
	50					55					60					

aac	cag	gac	ggt	ttc	tac	tac	ctg	tac	gct	aac	atc	tcc	ttc	aga	cat	240
Asn	Gln	Asp	Gly	Phe	Tyr	Tyr	Leu	Tyr	Ala	Asn	Ile	Ser	Phe	Arg	His	
65				70					75					80		

cac	gaa	acc	tct	ggt	tct	ggt	cca	acc	gac	tac	ctg	cag	ctg	atg	ggt	288
His	Glu	Thr	Ser	Gly	Ser	Val	Pro	Thr	Asp	Tyr	Leu	Gln	Leu	Met	Val	
				85					90					95		

18

tac gtt gtt aaa acc tct atc aaa atc cca tct tca cat aac ctg atg 336  
 Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met  
                   100                  105                  110

aaa ggt ggt tct acc aaa aac tgg tct ggt aac tct gaa ttc cat ttc 384  
 Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe  
                   115                  120                  125

tac tct atc aac gtt ggt ggt ttc ttc aaa ctg aga gct ggt gaa gaa 432  
 Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu  
                   130                  135                  140

atc tct atc cag gtt tct aac cct tct ctg ctg gac cca gac cag gac 480  
 Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp  
                   145                  150                  155                  160

gct acc tac ttc ggg gcc ttc aaa gtt cag gac atc gac 519  
 Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
                   165                  170

&lt;210&gt; 12

&lt;211&gt; 173

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<223> Description of Artificial Sequence: Fusion of  
 murine OPGL, residues 158-316 with C to S  
 mutation, and His tag

&lt;400&gt; 12

Met Lys His Gln His Gln His Gln His Gln His Gln His Gln Lys Pro  
           1                  5                  10                  15

Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro  
                   20                  25                  30

Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly  
                   35                  40                  45

Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val  
                   50                  55                  60

Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Ser Phe Arg His  
                   65                  70                  75                  80

His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val  
                   85                  90                  95

Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met  
                   100                  105                  110

Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe  
                   115                  120                  125



19

Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu  
 130 135 140

Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp  
 145 150 155 160

Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
 165 170

<210> 13

<211> 564

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fusion of  
 murine OPGL, residues 158-316 modified by  
 introduction of tetanus toxoid P30 epitope, and  
 His tag

<220>

<221> CDS

<222> (1)..(564)

<220>

<221> misc\_binding

<222> (1)..(42)

<223> His tag

<220>

<221> misc\_feature

<222> (43)..(336)

<223> Murine OPGL, residues 158-255

<220>

<221> misc\_feature

<222> (337)..(399)

<223> Tetanus toxoid P30 epitope

<220>

<221> misc\_feature

<222> (400)..(564)

<223> Murine OPGL, residues 262-316

<400> 13

atg aaa cac caa cac caa cat caa cat caa cat caa aaa cct 48  
 Met Lys His Gln His Gln His Gln His Gln His Gln Lys Pro  
 1 5 10 15

20

gaa gct cag cca ttc gct cat ctg acc atc aac gct gca tcg atc cct	96
Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro	
20 25 30	
tct ggt tct cat aaa gtt acc ctg tct tct tgg tat cac gac cgc ggt	144
Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly	
35 40 45	
tgg gct aaa atc tct aac atg acc ctg tct aac ggt aaa ctg aga gtt	192
Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val	
50 55 60	
aac cag gac ggt ttc tac tac ctg tac gct aac atc tgt ttc aga cat	240
Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His	
65 70 75 80	
cac gaa acc tct ggt tct gtt cca acc gac tac ctg cag ctg atg gtt	288
His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val	
85 90 95	
tac gtt gtt aaa acc tct atc aaa atc cca tct tca cat aac ctg atg	336
Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met	
100 105 110	
ttc aac aac ttc acc gtt tct ttc tgg ctg agg gta ccg aaa gtt tct	384
Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser	
115 120 125	
gct tct cac ctg gaa aac tgg tct ggt aac tct gaa ttc cat ttc tac	432
Ala Ser His Leu Glu Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr	
130 135 140	
tct atc aac gtt ggt ggt ttc ttc aaa ctg aga gct ggt gaa gaa atc	480
Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile	
145 150 155 160	
tct atc cag gtt tct aac cct tct ctg ctg gac cca gac cag gac gct	528
Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala	
165 170 175	
acc tac ttc ggg gcc ttc aaa gtt cag gac atc gac	564
Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp	
180 185	

&lt;210&gt; 14

&lt;211&gt; 188

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<223> Description of Artificial Sequence: Fusion of  
murine OPGL, residues 158-316 modified by  
introduction of tetanus toxoid P30 epitope, and  
His tag

&lt;400&gt; 14

```

Met Lys His Gln His Gln His Gln His Gln His Gln His Gln Lys Pro
 1              5              10              15

Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro
      20              25              30

Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly
      35              40              45

Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val
      50              55              60

Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His
      65              70              75              80

His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val
      85              90              95

Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met
      100             105             110

Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
      115             120             125

Ala Ser His Leu Glu Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr
      130             135             140

Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile
      145             150             155             160

Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala
      165             170             175

Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp
      180             185

```

&lt;210&gt; 15

&lt;211&gt; 546

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Fusion  
between murine OPGL, residues 158-316 with tetanus  
toxoid P2 epitope introduced, and His tag

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(546)

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; (1)..(42)

&lt;223&gt; His tag

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (43)..(336)

&lt;223&gt; Murine OPGL, residues 158-255

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (382)..(546)

&lt;223&gt; Murine OPGL, residues 262-316

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (337)..(381)

&lt;223&gt; Tetanus toxoid P2 epitope

&lt;400&gt; 15

atg	aaa	cac	caa	cac	caa	cat	caa	cat	caa	cat	caa	aaa	cct	48
Met	Lys	His	Gln	His	Gln	His	Gln	His	Gln	His	Gln	Lys	Pro	
1				5				10				15		

gaa	gct	cag	cca	ttc	gct	cat	ctg	acc	atc	aac	gct	gca	tcg	atc	cct	96
Glu	Ala	Gln	Pro	Phe	Ala	His	Leu	Thr	Ile	Asn	Ala	Ala	Ser	Ile	Pro	
			20				25					30				

tct	ggt	tct	cat	aaa	ggt	acc	ctg	tct	tct	tgg	tat	cac	gac	cgc	ggt	144
Ser	Gly	Ser	His	Lys	Val	Thr	Leu	Ser	Ser	Trp	Tyr	His	Asp	Arg	Gly	
		35					40					45				

tgg	gct	aaa	atc	tct	aac	atg	acc	ctg	tct	aac	ggt	aaa	ctg	aga	ggt	192
Trp	Ala	Lys	Ile	Ser	Asn	Met	Thr	Leu	Ser	Asn	Gly	Lys	Leu	Arg	Val	
		50				55					60					

aac	cag	gac	ggt	ttc	tac	tac	ctg	tac	gct	aac	atc	tgt	ttc	aga	cat	240
Asn	Gln	Asp	Gly	Phe	Tyr	Tyr	Leu	Tyr	Ala	Asn	Ile	Cys	Phe	Arg	His	
65				70					75					80		

cac	gaa	acc	tct	ggt	tct	ggt	cca	acc	gac	tac	ctg	cag	ctg	atg	ggt	288
His	Glu	Thr	Ser	Gly	Ser	Val	Pro	Thr	Asp	Tyr	Leu	Gln	Leu	Met	Val	
			85						90					95		

tac	ggt	ggt	aaa	acc	cct	atc	aaa	atc	caa	tct	tca	cat	aac	ctg	atg	336
Tyr	Val	Val	Lys	Thr	Pro	Ile	Lys	Ile	Gln	Ser	Ser	His	Asn	Leu	Met	
			100				105						110			

cag	tac	atc	aaa	gct	aat	tcg	aaa	ttc	atc	ggt	atc	acc	gaa	ctg	aac	384
Gln	Tyr	Ile	Lys	Ala	Asn	Ser	Lys	Phe	Ile	Gly	Ile	Thr	Glu	Leu	Asn	
		115				120						125				

<213> Artificial Sequence  
<223> Description of Artificial Sequence: Fusion  
between murine OPGL, residues 158-316 with tetanus  
toxoid P2 epitope introduced, and His tag

Met Lys His Gln His Gln His Gln His Gln His Gln His Gln Lys Pro  
1 5 10 15

Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro  
20 25 30

Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly  
35 40 45

Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val  
50 55 60

Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His  
65 70 75 80

His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val  
85 90 95

Tyr Val Val Lys Thr Pro Ile Lys Ile Gln Ser Ser His Asn Leu Met  
100 105 110

Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Asn  
115 120 125

Trp Ser Gly Asn Ser Glu Phe His Phe Tyr Ser Ile Asn Val Gly Gly  
130 135 140

24

Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile Ser Ile Gln Val Ser Asn  
 145 150 155 160

Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr Tyr Phe Gly Ala Phe  
 165 170 175

Lys Val Gln Asp Ile Asp  
 180

<210> 17

<211> 519

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fusion between  
 murine OPGL, residues 158-316 with tetanus toxoid  
 P2 epitope introduced, and His tag

<220>

<221> CDS

<222> (1)..(519)

<220>

<221> misc\_binding

<222> (1)..(42)

<223> His tag

<220>

<221> misc\_feature

<222> (43)..(432)

<223> Murine OPGL, residues 158-287

<220>

<221> misc\_feature

<222> (478)..(519)

<223> Murine OPGL, residues 303-316

<220>

<221> misc\_feature

<222> (433)..(477)

<223> Tetanus toxoid P2 epitope

<400> 17

atg aaa cac caa cac caa cat caa cat caa cat caa aaa cct 48  
 Met Lys His Gln His Gln His Gln His Gln His Gln Lys Pro  
 1 5 10 15

gaa gct cag cca ttc gct cat ctg acc atc aac gct gca tcg atc cct 96  
 Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro  
 20 25 30

25

tct ggt tct cat aaa gtt acc ctg tct tct tgg tat cac gac cgc ggt 144  
 Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly  
 35 40 45

tgg gct aaa atc tct aac atg acc ctg tct aac ggt aaa ctg aga gtt 192  
 Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val  
 50 55 60

aac cag gac ggt ttc tac tac ctg tac gct aac atc tgt ttc aga cat 240  
 Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His  
 65 70 75 80

cac gaa acc tct ggt tct gtt cca acc gac tac ctg cag ctg atg gtt 288  
 His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val  
 85 90 95

tac gtt gtt aaa acc tct atc aaa atc cca tct tca cat aac ctg atg 336  
 Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met  
 100 105 110

aaa ggt ggt tct acc aaa aac tgg tct ggt aac tct gaa ttc cat ttc 384  
 Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe  
 115 120 125

tac tct atc aac gtt ggt ggt ttc ttc aaa ctg aga gct ggt gaa gaa 432  
 Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu  
 130 135 140

cag tac atc aaa gct aat tcg aaa ttc atc ggt atc acc gaa ctg gac 480  
 Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Asp  
 145 150 155 160

gct acc tac ttc ggg gcc ttc aaa gtt cag gac atc gac 519  
 Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
 165 170

&lt;210&gt; 18

&lt;211&gt; 173

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<223> Description of Artificial Sequence: Fusion between  
 murine OPGL, residues 158-316 with tetanus toxoid  
 P2 epitope introduced, and His tag

&lt;400&gt; 18

Met Lys His Gln His Gln His Gln His Gln His Gln His Gln Lys Pro  
 1 5 10 15

Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro  
 20 25 30

Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly

26

35	40	45
Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val		
50	55	60
Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His		
65	70	75
His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val		
	85	90
Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met		
	100	105
Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe		
	115	120
Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu		
	130	135
Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Asp		
145	150	155
Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp		
	165	170

&lt;210&gt; 19

&lt;211&gt; 519

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Fusion between murine OPGL, residues 158-316 with tetanus toxoid P30 epitope introduced, and His tag

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(519)

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; (1)..(42)

&lt;223&gt; His tag

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (43)..(231)

&lt;223&gt; Murine OPGL, residues 158-220

&lt;220&gt;



&lt;221&gt; misc\_feature

&lt;222&gt; (295)..(519)

&lt;223&gt; Murine OPGL, residues 242-316

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (232)..(294)

&lt;223&gt; Tetanus toxoid P30 epitope

&lt;400&gt; 19

atg aaa cac caa cac caa cat caa cat caa cat caa cat caa aaa cct	48
Met Lys His Gln His Gln His Gln His Gln His Gln His Gln Lys Pro	
1 5 10 15	
 gaa gct cag cca ttc gct cat ctg acc atc aac gct gca tcg atc cct	96
Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro	
20 25 30	
 tct ggt tct cat aaa gtt acc ctg tct tct tgg tat cac gac cgc ggt	144
Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly	
35 40 45	
 tgg gct aaa atc tct aac atg acc ctg tct aac ggt aaa ctg aga gtt	192
Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val	
50 55 60	
 aac cag gac ggt ttc tac tac ctg tac gct aac atc tgt ttc aac aac	240
Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Asn Asn	
65 70 75 80	
 ttc acc gtt tct ttc tgg ctg agg gta ccg aaa gtt tct gct tct cac	288
Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His	
85 90 95	
 ctg gaa gtt aaa acc tct atc aaa atc cca tct tca cat aac ctg atg	336
Leu Glu Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met	
100 105 110	
 aaa ggt ggt tct acc aaa aac tgg tct ggt aac tct gaa ttc cat ttc	384
Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe	
115 120 125	
 tac tct atc aac gtt ggt ggt ttc ttc aaa ctg aga gct ggt gaa gaa	432
Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu	
130 135 140	
 atc tct atc cag gtt tct aac cct tct ctg ctg gac cca gac cag gac	480
Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp	
145 150 155 160	
 gct acc tac ttc ggg gcc ttc aaa gtt cag gac atc gac	519
Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp	
165 170	

<210> 20  
 <211> 173  
 <212> PRT  
 <213> Artificial Sequence  
 <223> Description of Artificial Sequence: Fusion between  
 murine OPGL, residues 158-316 with tetanus toxoid  
 P30 epitope introduced, and His tag

<400> 20  
 Met Lys His Gln His Gln His Gln His Gln His Gln His Gln Lys Pro  
 1 5 10 15  
 Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro  
 20 25 30  
 Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly  
 35 40 45  
 Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val  
 50 55 60  
 Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Asn Asn  
 65 70 75 80  
 Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His  
 85 90 95  
 Leu Glu Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met  
 100 105 110  
 Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe  
 115 120 125  
 Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu  
 130 135 140  
 Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp  
 145 150 155 160  
 Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
 165 170

<210> 21  
 <211> 68  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: Synthetic PCR  
 primer

<400> 21  
agctgcaggt agtcggttgg aacagaacca gaggtttcgt gatgtctgaa acagatgtta 60  
gcgtacag 68

<210> 22  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic PCR  
primer

<400> 22  
ctcatctgac catcaacgct gcat 24

<210> 23  
<211> 64  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic PCR  
primer

<400> 23  
tttcggtacc ctccagccaga aagaaacggt gaagttgttg aaacagatgt tagcgtacag 60  
gtag 64

<210> 24  
<211> 61  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic PCR  
primer

<400> 24  
tgagggtacc gaaagtttct gcttctcacc tggaagttaa aaccctatc aaaatccaat 60  
c 61

<210> 25  
<211> 63  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic PCR

## primer

&lt;400&gt; 25

tttcggtacc ctcagccaga aagaaacggt gaagttgttg aacatcaggt tatgtgaaga 60  
ttg 63

&lt;210&gt; 26

&lt;211&gt; 62

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic PCR  
primer

&lt;400&gt; 26

tgagggtacc gaaagtttct gcttctcacc tggaaaactg gtctggtaac tctgaattcc 60  
at 62

&lt;210&gt; 27

&lt;211&gt; 79

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic PCR  
primer

&lt;400&gt; 27

tacctgcagc tgatggttta cgttggttaa acccctatca aaatccaatc ttcacataac 60  
ctgatgcagt acatcaaag 79

&lt;210&gt; 28

&lt;211&gt; 83

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic PCR  
primer

&lt;400&gt; 28

tggaattcag agttaccaga ccagttcagt tcggtgatac cgatgaattt cgaattagct 60  
ttgatgtact gcatcaggtt atg 83

&lt;210&gt; 29

&lt;211&gt; 49

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic PCR  
primer

<400> 29

gaatttcgaa ttagctttga tgtactgttc ttcaccagct ctcagtttg

49

<210> 30

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic PCR  
primer

<400> 30

gctaattcga aattcatcgg tatcaccgaa ctggacgcta cctacttcgg ggc

53

<210> 31

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic PCR  
primer

<400> 31

cttactagtc gatgtcctga actttg

26

<210> 32

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic PCR  
primer

<400> 32

agtggaattc agagttacca gaccagtttt tggtagaacc acctttcatc aggttatgtg 60  
aagatgggat ttg 74

<210> 33

<211> 65

<212> DNA

<213> Clostridium tetani

&lt;400&gt; 33

actacctgca gctgatgggtt tacgttggtta aaacctctat caaaatccca tcttcacata 60  
acctg 65

&lt;210&gt; 34

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Clostridium tetani

&lt;400&gt; 34

Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu  
1 5 10 15

&lt;210&gt; 35

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Clostridium tetani

&lt;400&gt; 35

Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser  
1 5 10 15

Ala Ser His Leu Glu

20

## INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/DK 99/00481

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/62 C12N15/86 C12N15/12 C12N5/10 C12N1/21  
 C12N1/19 C07K14/705 A61K39/00 A61K31/713 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FULLER K ET AL: "TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts" J EXP MED, vol. 188, no. 5, 7 September 1998 (1998-09-07), pages 997-1001, XP000876582 cited in the application	
A	WO 98 28426 A (IMMUNEX CORP) 2 July 1998 (1998-07-02) claim 34; examples 10,13	
A	WO 98 25958 A (SCHERING CORP) 18 June 1998 (1998-06-18)	
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
 "&" document member of the same patent family

Date of the actual completion of the international search

9 February 2000

Date of mailing of the international search report

28/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, 0

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 99/00481

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 23614 A (AMGEN INC ; LACEY DAVID L (US); BOYLE WILLIAM J (US); CALZONE FRANK) 3 July 1997 (1997-07-03) cited in the application -----	
A	WO 97 20063 A (UNIV COLUMBIA ; BIOGEN INC (US)) 5 June 1997 (1997-06-05) abstract -----	
A	WO 95 27058 A (UNIV UTAH ; RECHSTEINER MARTIN C (US); REALINI CLAUDIO A (US)) 12 October 1995 (1995-10-12) -----	
P, X	WO 98 46751 A (AMGEN INC ; BOYLE WILLIAM J (US)) 22 October 1998 (1998-10-22) claims 35,36 -----	1,53-56



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/ 00481

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1-29 and 45  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Appl. Application No

PCT/DK 99/00481

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
W0 9828426	A	02-07-1998	AU 713471 B AU 5618098 A AU 713473 B AU 5718498 A EP 0951551 A EP 0946725 A W0 9828424 A	02-12-1999 17-07-1998 02-12-1999 17-07-1998 27-10-1999 06-10-1999 02-07-1998
W0 9825958	A	18-06-1998	AU 5697098 A EP 0948530 A	03-07-1998 13-10-1999
W0 9723614	A	03-07-1997	AU 710587 B AU 1468697 A BG 101813 A CA 2210467 A CN 1182452 A CZ 9702538 A DE 19654610 A EP 0784093 A EP 0870023 A FR 2742767 A GB 2312899 A, B HU 9801122 A JP 11503616 T NO 973699 A NZ 326579 A PL 321938 A TR 970550 A	23-09-1999 17-07-1997 30-09-1998 03-07-1997 20-05-1998 17-03-1999 26-06-1997 16-07-1997 14-10-1998 27-06-1997 12-11-1997 28-08-1998 30-03-1999 21-10-1997 28-01-1999 05-01-1998 21-07-1997
W0 9720063	A	05-06-1997	AU 709550 B AU 1143897 A CA 2238879 A EP 0880597 A	02-09-1999 19-06-1997 05-06-1997 02-12-1998
W0 9527058	A	12-10-1995	AU 7353094 A EP 0755444 A	23-10-1995 29-01-1997
W0 9846751	A	22-10-1998	US 5843678 A AU 7120598 A EP 0975754 A ZA 9803189 A	01-12-1998 11-11-1998 02-02-2000 16-10-1998